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Abstract
Tumor angiogenesis is a hallmark of cancer, and plays a critical role in tumor growth, expansion, and
metastasis. Both physiological and pathological angiogenesis is assumed to be regulated by the balance
between pro and anti-angiogenic factors. One of the best characterized and most potent pro-angiogenic
regulators is vascular endothelial growth factor, or VEGF. Calcineurin signaling is an important mediator of
VEGF signaling in endothelial cells. Negative regulation of calcineurin by increased expression of its
endogenous inhibitor, Down Syndrome Candidate Region-1 (DSCR1), suppresses tumor growth and
angiogenesis. However, a potent pharmacological calcineurin inhibitor, the commonly used
immunosuppressant cyclosporin A (CsA), significantly increases the incidence of cancer in organ transplant
recipients. The mechanism by which CsA promotes cancer in this patient population is not well understood
and despite the significance of calcineurin signaling in endothelial cells, the consequences of CsA on tumor
angiogenesis has not been investigated. Using an in vivo model of skin carcinogenesis, we show that long-term
CsA treatment promotes tumor growth and angiogenesis. Further our data indicate that treatment of
endothelial cells in vitro with CsA increases proliferation and migration, in a calcineurin-independent manner.
Our studies reveal that CsA-induced endothelial cell activation was due to the interaction of CsA with
cyclophilin D located on the mitochondrial inner membrane. CsA treatment in endothelial cells increased
mitochondrial membrane potential and mitochondrial reactive oxygen species production, and was associated
with sustained mitogen-activated protein kinase (MAPK) activity. Co-treatment with antioxidants
significantly abrogated CsA-induced endothelial cell activation. Furthermore, mice treated with antioxidants
were protected against CsA-mediated tumor progression. Taken together, these findings show that CsA
functions independent of calcineurin to potentiate tumor growth by promoting tumor angiogenesis via
mitochondrial reactive oxygen species production. This work identifies a previously undescribed mechanism
underlying a significantly adverse off-target effect of CsA and suggests that co-treatment with antioxidants
may inhibit the tumor promoting effects of CsA.
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ABSTRACT 
EFFECT OF CYCLOSPORIN A ON THE TUMOR MICROENVIRONMENT 
Alice Yao Zhou 
Sandra Ryeom 
 
Tumor angiogenesis is a hallmark of cancer, and plays a critical role in tumor growth, 
expansion, and metastasis. Both physiological and pathological angiogenesis is assumed 
to be regulated by the balance between pro and anti-angiogenic factors. One of the best 
characterized and most potent pro-angiogenic regulators is vascular endothelial growth 
factor, or VEGF. Calcineurin signaling is an important mediator of VEGF signaling in 
endothelial cells. Negative regulation of calcineurin by increased expression of its 
endogenous inhibitor, Down Syndrome Candidate Region-1 (DSCR1), suppresses tumor 
growth and angiogenesis. However, a potent pharmacological calcineurin inhibitor, the 
commonly used immunosuppressant cyclosporin A (CsA), significantly increases the 
incidence of cancer in organ transplant recipients.  The mechanism by which CsA 
promotes cancer in this patient population is not well understood and despite the 
significance of calcineurin signaling in endothelial cells, the consequences of CsA on 
tumor angiogenesis has not been investigated. Using an in vivo model of skin 
carcinogenesis, we show that long-term CsA treatment promotes tumor growth and 
angiogenesis. Further our data indicate that treatment of endothelial cells in vitro with 
CsA increases proliferation and migration, in a calcineurin-independent manner. Our 
studies reveal that CsA-induced endothelial cell activation was due to the interaction of 
CsA with cyclophilin D located on the mitochondrial inner membrane. CsA treatment in 
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endothelial cells increased mitochondrial membrane potential and mitochondrial reactive 
oxygen species production, and was associated with sustained mitogen-activated protein 
kinase (MAPK) activity. Co-treatment with antioxidants significantly abrogated CsA-
induced endothelial cell activation. Furthermore, mice treated with antioxidants were 
protected against CsA-mediated tumor progression. Taken together, these findings show 
that CsA functions independent of calcineurin to potentiate tumor growth by promoting 
tumor angiogenesis via mitochondrial reactive oxygen species production. This work 
identifies a previously undescribed mechanism underlying a significantly adverse off-
target effect of CsA and suggests that co-treatment with antioxidants may inhibit the 
tumor promoting effects of CsA.  
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CHAPTER 1: INTRODUCTION 
 
Angiogenesis 
 
Physiological angiogenesis 
The circulatory system provides multi-cellular organisms with oxygen, nutrients, 
and signaling molecules necessary for growth and homeostasis. Vertebrate vasculature is 
defined as a closed system of elastic arteries that distribute blood to distant tissues, 
capillary beds where gas exchange occurs, a venous system that returns deoxygenated 
blood, and a muscular pump that moves the blood through at a rate adaptive to the 
metabolic demands of the organism. This mode of nutrient and oxygen delivery has been 
conserved with relatively few changes throughout evolution (Axnick & Lammert 2012).  
Developmentally, the vertebrate vascular system appears early on in 
embryogenesis, starting in the primitive streak. Endothelial precursors develop into a 
primary plexus, dorsal aorta, and the cardinal vein, before joining together to form the 
preliminary circulatory system. The de novo formation of vessel from endothelial 
precursors early in development is termed vasculogenesis (Jain 2003). In addition to 
providing a rudimentary circulatory system for the developing embryo, vasculogenesis 
also plays a role in shaping organogenesis and has been shown to provide trophic signals 
for liver, pancreatic, and kidney development (Coultas et al. 2005).  
Once a primitive vascular template has been established through vasculogenesis, 
the vascular plexus expands and grows into a mature circulatory system by means of 
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vascular sprouting and remodeling from existing vessels, a process known as 
angiogenesis (Jain 2003) which is responsible for the majority of vascular development. 
Angiogenesis is a tightly regulated process that continues throughout development, with 
increasing interactions and specificity towards the organ systems it supplies.  
The angiogenic process can be roughly separated into four stages: initiation of 
sprouting, sprouting outgrowth, sprout fusion / lumen formation, and stabilization/ 
maturation of the vessel (Jain 2003; Carmeliet 2000) (Fig 1.1.). These stages are 
contiguous with one another and are tightly regulated by pro and anti-angiogenic 
regulators to ensure proper vessel growth. This process is most prominent in fetal 
development, but also occurs later in life during physiological and pathological 
angiogenesis in adults (Carmeliet 2005).  
The first step of angiogenesis is the stimulation of angiogenic growth that is 
primarily mediated by the secreted vascular endothelial growth factor A (VEGFA), a 
critical pro-angiogenic molecule. VEGFA is part of a large family of angiogenic 
regulators that include VEGFB, VEGFC, VEGFD, and placental growth factor (PlGF) 
(Coultas et al. 2005) (Table 1.1). The predominant effect of VEGFA on nascent 
endothelial cells is to promote migration, proliferation, and differentiation. The effect of 
VEGFA on developing vessels is regulated by various splice variants and receptor 
signaling such as the anti-angiogenic β-isoform VEGFA splice variant and the decoy 
receptor VEGFR1, which sequesters VEGFA with minimal angiogenic signaling effects 
(Adams & Alitalo 2007) (Table 1.2). Chemotactic gradients, formed from pro- and 
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inhibitory signals, select individual endothelial cells to sprout from the parent vessel. 
Sprouting endothelial cells actively degrade extracellular matrix in the migratory front,  
 
Fig. 1.1. Overview of physiological angiogenesis. (A) Activation of endothelial cells 
through chemotactic gradients, followed by (B) migration through the vascular 
smooth muscle cell barrier and proliferation, guided by pro- and anti-angiogenic 
signals. (C) The vessel continues to elongate and may fuse with another growing 
vessel before (D) excessive vessels are pruned, lumen formation finalizes, and 
vascular smooth muscle cells are recruited.  
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change their apical-basal cellular polarity, and laterally inhibit neighboring endothelial 
 
Table 1.1 VEGF family members. Bolded terms indicate dominant form or effect 
Ligand Size – isoforms Expression Receptor Effect on 
angiogenesis 
VEGF-A VEGFA121 (soluble)  
VEGFA165 (intermediate 
solubility) VEGFA165b (inhibitory) 
VEGFA189 (heparin bound) 
VEGFA206 (heparin bound) 
 VEGFR1  
VEGFR2 
NPR1 
Pro-angiogenesis 
↑ Permeability 
Bone turnover 
Monocyte chemokine 
HSC mobilization 
VEGF-B VEGFB167 (heparin bound) 
VEGFB186 (soluble) 
Muscle 
Myocardium 
Brown fat 
VEGFR1 
NP1 
Unclear 
Weakly mitogenic 
VEGF-C VEGFC (29/31kDa – unprocessed)  
VEGFC (21kDa – processed) 
Fetus: 
Lymph vessels 
VEGFR2 
VEGFR3 
Lymphangiogenesis 
VEGF-D   Fetus: lung, skin VEGFR2 
VEGFR3 
Angiogenesis and 
lymphangiogenesis 
PlGF PlGF131 
PlGF152 (heparin bound) 
PlGF203 
PlGF224 (heparin bound) 
Placenta 
Retina 
Heart  
Lung 
VEGFR1 
NP1 
Placental, ovarian, 
and retinal 
angiogenesis 
 
Table 1.2 VEGF receptors. Bolded terms indicate dominant effect.  
Receptor Alternativ
e forms 
Ligand Expression Pairing 
Partner 
Signaling 
Outcome 
VEGFR1 
(Flt-1) 
Soluble 
VEGFR1 
(inhibitory) 
VEGFA 
VEGFB 
PlGF 
endothelium, 
osteoblasts, 
macrophages, renal 
cells, hematopoietic 
stem cells (HSC), 
placenta trophoblasts 
VEGFR1 
VEGFR2 
+VEGFR2 = weak 
angiogenesis 
+VEGFR1 = 
inhibitory 
Soluble VEGFR1 = 
decoy receptor 
VEGFR2 
(KDR/Fl
k-1) 
 VEGFA 
VEGFC 
VEGFD 
endothelium,  
neurons, osteoblasts, 
megakaryocytes and 
HSC 
VEGFR1 
VEGFR2 
VEGFR3 
VEGFR2 
homodimerization 
major mediator of 
angiogenesis 
VEGFR3 
(Flt-4) 
 VEGFC 
VEGFD 
Lymphatic 
endothelial cells 
VEGFR2 
VEGFR3 
Lymph-
angiogenesis 
NP1 Soluble 
NP1 
(inhibitory) 
VEGFA165 
VEGFB 
and PlGF 
 
arterial endothelium,  
lung, heart, liver, 
kidney, pancreas, 
bone marrow  
VEGFR2 Enhances VEGFA-
VEGFR2 signaling 
Soluble 
NP1=decoy 
receptor 
NP2  VEGFA, 
VEGFC 
and PlGF 
lymphatic, venous 
endothelium,  lung, 
heart, liver, kidney, 
pancreas, bone 
marrow  
VEGFR2 Unclear 
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cells from undergoing the same process. Interplay between the Notch-delta ligand like 4  
(DLL4) and the VEGFA-VEGFR signaling plays a crucial part in this sprouting process 
(Adams & Alitalo 2007; Jain 2003). Tip cell selection is not completely understood, but 
is thought to be due to small differences in VEGFR2 expression or VEGFA in the local 
environment along with crosstalk with Notch signaling (Blanco & Gerhardt 2013).  
The establishment of tip cells is closely associated with the conversion of cells 
immediately behind the tip cell into stalk cells, which follow the tip cells as the sprout 
extends outwards, and proliferate to lengthen the nascent vessel. Stalk cells will 
proliferate in response to guidance by the tip cell, which itself does not divide. Tip cell 
maintenance, like in sprout selection, is thought to be due to interplay between the Notch-
DLL4 and VEGFA-VEGFR pathways, with increased expression of both in tip cells 
(Adams & Alitalo 2007).  
When the budding vessel encounters existing capillaries or other growing 
endothelial sprouts, it establishes adhesive cellular junctions to fuse with the encountered 
vessel. Inappropriate junction formation is prevented by various adhesive and repulsive 
signals. Upon fusion with another vessel, the newly developed vessel then lumenizes to 
allow for eventual fluid flow (Adams & Alitalo 2007). This lumenization process is 
poorly understood, but recent evidence shows it occurs through ‘cord hollowing’ where a 
cylindrical column of cells drastically reshape around a hollow core to form a 
multicellular lumenized tube (Nelson & Beitel 2009).  
Naked endothelial cells that constitute newly formed vessels are unstable and 
leaky and require stabilization through pericyte coverage. Pericytes and the closely 
6 
 
related vascular smooth muscle cells are contractile, mesenchymal cells that regulate 
vessel contraction or dilation, permeability, and immune cell infiltration. In the 
developing vessel, platelet derived growth factor (PDGF), secreted by endothelial cells, 
recruits and attracts pericytes. Subsequent pericyte coverage and stabilization of the 
vessel is, in part, regulated by the Angiopoietin-Tie2 system. Pericyte-derived soluble 
molecule angiopoietin 1 (Ang-1) promotes endothelial cell survival and mural cell 
attachment through binding to Tie-2 receptors on endothelial cells. Negative regulators 
such as angiopoietin 2 (Ang-2), which also binds Tie-2 receptors, act to antagonize vessel 
stability and work in conjunction with Ang-1 to prune and guide vessel formation and 
maturation (Jain 2003).  
Angiogenesis is an active process that occurs largely during development. Once 
the vascular network have been formed and stabilized, it remains relatively static 
throughout life. Second only to cells in the nervous system, endothelial cells are one of 
the longest-lived cells in the body (Bergers & Benjamin 2003). Angiogenesis in 
adulthood is an infrequent event and occurs in response to a precipitating incident such as 
wound healing, endometrial growth during the menstrual cycle, or placental growth 
during pregnancy (Carmeliet 2005). When it does occur, physiological angiogenesis in 
adults is also tightly regulated and follows the same steps and pathways as in 
developmental angiogenesis.  
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Pathological angiogenesis 
While physiological angiogenesis in adults is a rare event, many pathological 
conditions feature dysregulated vessel growth. In preeclampsia and ischemic heart 
disease, the angiogenic response is insufficient to meet metabolic needs, resulting in 
inadequate tissue perfusion. In the majority of disease states involving pathological 
angiogenesis the angiogenic switch is inappropriately activated, leading to aberrant vessel 
formation. While pathological angiogenesis occurs through a similar fashion as 
physiological angiogenesis, the tightly controlled factors and temporal steps that result in 
functional vessels are dysregulated, and vessel maturation in particular, is absent or 
abnormal in the disease state. The predominant pathological conditions that involve 
aberrant angiogenesis are either inflammatory or malignant.  
 
Diabetic retinopathy 
The retina has a highly regulated and organized vascular anatomy to balance 
perfusion with light detection. Areas of high photoreceptor density such as the fovea, 
have greatly decreased vascularization (Gariano & Gardner 2005). Pathological retinal 
angiogenesis that occurs in diabetes is the leading cause of irreversible vision impairment 
and blindness in adults. Diabetic retinopathy occurs in 20% of patients with diabetes, a 
systemic metabolic and inflammatory disease, and is characterized by microaneurysms 
and exudative changes in the retinal vessels, areas of ischemia, abnormal vessel growth, 
friable vessels, and hemorrhages (Gariano & Gardner 2005; Gardner 2012). This process 
is progressive, occurring over years, and is dependent on the overall metabolic health of 
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the individual. Untreated, visual acuity will progressively decline and, in severe cases, 
marked by episodic events of hemorrhaging or retinal detachment (Gardner 2012). As the 
major inducer of angiogenesis, VEGFA plays a significant role in diabetic retinopathy. In 
combination with inflammatory cytokines and chemokines, accumulation of VEGFA in 
the vitreous humor results in increased vascular permeability of existing vessels and 
initiates the formation of new vessels (Gariano & Gardner 2005). However, pericyte 
coverage of the newly formed vessels is low, which in combination with  pericyte loss 
from existing vessels, results in weak and unstable retinal vasculature that dilate and leak. 
This abnormal vessel growth paradoxically produces hypoxic conditions in the vitreous, 
which induces the hypoxia inducible factor (HIF) to further upregulate pro-angiogenic 
responses (Gariano & Gardner 2005). The most common treatment for diabetic 
retinopathy involves vessel ablation by laser treatment, which prevents hemorrhages and 
decreases exudate, but is a symptomatic treatment at best. Single target anti-angiogenic 
therapies with anti-VEGF treatments have shown only partial success, as diabetic 
retinopathy is complicated by the involvement of inflammatory molecules which also 
affects vessel function (Gardner 2012). Therefore, the development of anti-angiogenic 
treatments for diabetic retinopathy is still an area of active research. 
 
Exudative age-related macular degeneration 
The second most common cause of blindness in the elderly is age-related macular 
degeneration (AMD), an inflammatory disease confined to the retina. As the name 
implies, macular degeneration is the progressive and selective loss of vision in the macula, 
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or center of the visual field. This disease occurs in two types, dry/non-exudative AMD, 
characterized by plaque-like formations called drusden, and wet/exudative AMD, a more 
severe form characterized by neovascularization. As with diabetic retinopathy, the newly 
formed vessels associated with wet AMD is dysfunctional, leaky, and fragile, causing 
functional impairment of the retina and can lead to retinal detachment (Rattner & 
Nathans 2006). Previously, clinical management of wet AMD consists of symptom relief 
through laser ablation therapy. In recent years, treatment options have improved due to 
the use of anti-VEGF therapy to staunch the growth of new vessels (Dadgostar & 
Waheed 2008). Injections of anti-VEGF antibodies such as Bevacizumab and 
Ranibizumab directly into the retinal space have not only slowed the progression of 
disease but also significantly improved vision, and is now the gold standard treatment for 
wet AMD (CATT Research Group 2011; Dadgostar & Waheed 2008).   
 
Tumor angiogenesis 
Perhaps the most diverse and heterogeneous example of pathological 
angiogenesis is tumor angiogenesis. The vascular requirement of solid tumors was first 
recognized in the early 1970s by Judah Folkman. Given the rogue nature of tumor growth, 
perfusion of a solid malignant growth can be a rate-limiting step for its expansion. The 
importance of angiogenesis for malignant progression is reflected in its inclusion as one 
of the original six hallmarks of cancer (Hanahan & Weinberg 2000). 
Neoplastic angiogenesis is varied and heterogeneous depending on tumor type, 
tumor stage, and other microenvironment cues. It is, however, almost always 
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disorganized, tortuous, and inefficient. Tumor vasculature does not follow hierarchical 
divisions that mark normal vasculature such as arteries, capillary beds, and veins, with 
hemodynamic considerations. Instead, neoplastic vessels are irregularly shaped and 
dilated, with little or no distinction between arterioles, venules, or capillaries. Vessel 
anastomosis may be abnormal or absent, explaining the presence of dead-end vessels. 
Due to the chaotic nature of tumor vessels, perfusion is often poor with areas of 
hemostasis or even reversal of flow. In addition to abnormal structure, the vessel itself is 
often vastly haphazard and irregular with variable cellular organization and improper cell 
junctions. These vessels display patchy and irregular mural cell coverage which, when 
present, is also abnormal and dysfunctional. In combination with irregular hemodynamics, 
these erratic vessels with poor vessel structure are often leaky, exudative, and 
paradoxically under-perfused (Bergers & Benjamin 2003). Due to the dysfunctional 
nature of neoplastic vessels and continuous remodeling that occurs in tumor vessels, 
tumor perfusion can range from very hypoxic to very oxygenated, and can vary spatially 
and temporally (Bergers & Benjamin 2003). The tumor microenvironment is a harsh and 
variable environment; therefore, cancer cells that survive in this environment often have 
decreased metabolic and oxygen demands, enabling them to survive within the inefficient 
vascular network.  
As a tissue expands, it outgrows its oxygen and nutrient supply and becomes 
hypoxic, at which point hypoxia-responsive genes, regulated by HIF, are upregulated. 
Growing tumor tissue, under the duress of hypoxia, secretes pro-angiogenic factors, the 
most notable being VEGFA, but also can include fibroblast growth factor (FGF), placenta 
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induced growth factor (PIGF), and transforming growth factor-β (TGF-β). VEGFA alone 
is able to initiate the angiogenic response, promoting sprouting from nearby vessels. 
Since tumor growth is not organized or patterned, its promotion of angiogenesis is 
similarly disorganized due to a misbalance between pro and anti-angiogenic factors 
(Hickey & Simon 2006; Bergers & Benjamin 2003). While pericyte coverage in tumor 
vasculature is found to be variable depending on the tumor subtype and the study 
methods, the general consensus is that they are abnormal and dysfunctional (Raza et al. 
2010). Tumor associated pericyte-like cells have weak endothelial cell contacts, and have 
been shown to secrete VEGF, further aggravating vessel growth and leakiness (Raza et al. 
2010; Bergers & Benjamin 2003). 
The angiogenic process is a tight balance of pro and anti-angiogenic regulators. In 
physiological angiogenesis, endogenous anti-angiogenic proteins help guide and structure 
new vessel growth, as well as maintain vascular quiescence and prevent excessive growth. 
Endogenous anti-angiogenic proteins originate from multiple sources; many are derived 
from extracellular matrix proteins, others are inflammatory molecules, and some are 
soluble decoy receptors (Folkman 2004). The extracellular matrix and stroma 
surrounding existing vessels exert multiple layers of control and regulation in vessel 
growth. As angiogenesis is a rare event in adult vasculature, the stromal environment 
strongly inhibit angiogenesis, and cleaved fragments of many extracellular matrix 
proteins, such as endostatin from collagen XVIII and tumstatin from collagen IV 
(O’Reilly et al. 1997; Maeshima et al. 2000), act to inhibit new vessel growth. 
Inflammatory molecules such as IFN-α, IL-1, IL-4, and IL-8 have also been shown to 
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have anti-angiogenic properties (Ribatti 2009). Endostatin, angiostatin, and 
thrombospondin are the best characterized endogenous anti-angiogenic factors. Loss of 
these factors, as in thrombospondin-1 null mice, results in accelerated tumor growth with 
increased angiogenesis (Good et al. 1990). Therefore, endogenous anti-angiogenic factors 
act as a natural defense system against pathological angiogenesis. Several drugs 
exploiting these endogenous anti-angiogenic factors have shown promise in clinical trials. 
For example, endostatin, in combination with chemotherapy, showed efficacy in several 
clinical trials (Rong et al. 2012). The use of these drugs, however, is complicated by the 
high dose needed, short half-life, repeated administration, and potential toxicities. While 
they have potential for treating solid cancers, more pharmacological and clinical studies 
are needed.  
 
Anti-angiogenic therapy 
The neovascular requirement of solid tumors opens a promising field for the 
development of new anti-cancer drugs that target angiogenesis. A common 
misunderstanding of anti-angiogenic therapy is that it serves only to cause vessel 
regression, starving the tumor of oxygen and preventing tumor progression. While this 
does occur,  anti-angiogenic therapy has also been shown to cause vessel normalization 
(Carmeliet & Jain 2011). Tumor vessels are inefficient in delivering oxygen and nutrients, 
and in the setting of treatment, chemotherapeutic drugs. Therefore, in combination with 
chemotherapeutic treatment, improving tumor vessel function actually results in better 
drug delivery to the intended tissue (Carmeliet & Jain 2011). Therapies that target tumor 
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vessels are focused on vessel maturation and stabilization. VEGF withdrawal occurs in 
the maturation stages of physiological angiogenesis and contributes to endothelial cell 
quiescence. In line with this, multiple anti-angiogenic therapies were put into clinical trial 
with the intent of vessel normalization, better drug delivery, and ultimately tumor 
regression. In targeting the VEGF pathway, several anti-angiogenic drugs have been 
developed: bevacizumab is a ligand-trapping monoclonal antibody, sorafenib and 
sunitinib are kinase inhibitors that inhibit VEGFR2 (Bergers & Hanahan 2008). 
Given the complexity of angiogenesis, its dysregulation in tumor angiogenesis, 
and the mutational propensity of cancer cells, it is not surprising that anti-angiogenic 
therapy has been clinically disappointing. While clinical trials utilizing anti-angiogenic 
therapies initially showed promise with tumoristatic activity and rare tumoricidal activity, 
most, if not all anti-angiogenic therapies eventually fail with tumor progression and 
growth (Bergers & Hanahan 2008; Weis & Cheresh 2011). This has been attributed to a 
number of resistance mechanisms. In response to anti-angiogenic treatment, tumors often 
develop evasive resistance to the anti-VEGF agent used, switching from reliance on the 
VEGF pathway to alternative pro-angiogenic signals, such as FGF, PDGF, or 
angiopoietins. Secondly, hypoxia induced by the anti-angiogenic agents not only 
upregulates pro-angiogenic signals, but also induces the recruitment of various bone 
marrow derived cells such as vascular progenitors and vascular modulatory cells, which 
can independently contribute to the tumor vasculature. Thirdly, anti-angiogenic therapy 
in the absence of other chemotherapeutic agents will promote vessel normalization by 
increasing pericyte coverage. This increases oxygen and nutrient delivery to the tumor 
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despite lowering microvessel density. Lastly, tumors by their nature are highly adaptive. 
With the loss of de novo vessel growth, cancers cells that are more invasive have a 
survival advantage, resulting in increased local invasion and distant metastasis. For 
example, in response to regression of the anti-VEGF-sensitive tumor vessels, gliomal 
cells have been shown to co-opt normal vessels that are insensitive to anti-VEGF therapy, 
and track along those conduits to invade locally (Bergers & Hanahan 2008). The failure 
of the initial trials using anti-angiogenic therapy highlights the complexity of tumor 
angiogenesis, and targeting it successfully requires further understanding of the interplay 
between tumor cells and their microenvironment.  
 
 
Calcineurin and Angiogenesis 
 
Calcineurin biology 
Calcineurin is a calcium regulated ser/thr phosphatase conserved from yeast to 
humans (Krinks 1979). It is a ubiquitous signaling pathway downstream of many 
extracellular signals with tissue-specific functions (Rusnak & Mertz 2000). Discovered as 
a binding partner to the immunosuppressant cyclosporin A (CsA), the calcineurin 
pathway (Liu et al. 1991) (Fig. 1.2.) was first delineated in T cells (Ho et al. 1996; 
Clipstone & Crabtree 1992), and was later found to have important roles in neuronal 
survival, myocardiocyte response to stress, vascular patterning, and angiogenesis 
(Crabtree & Olson 2002). In response to an activating signal, such as T cell receptor 
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(TCR) activation, there is an increase in intracellular calcium that binds to the calcium 
modulated protein, calmodulin, which in turn activates the calcineurin complex.  
 
Fig. 1.2. Overview of calcineurin signaling in endothelial cells.  
Calcineurin is composed of the catalytic subunit calcineurin A and the regulatory 
subunit B. In absence of calcium and calmodulin binding, calcineurin A is kept inactive 
with an auto-inhibitory loop. When calmodulin is bound to calcium, it binds to 
calcineurin B, which moves the auto-inhibitory loop out of position, allowing calcineurin 
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to be enzymatically active. When active, calcineurin dephosphorylates its downstream 
substrates, the most notable being the nuclear factor of activated T-cells (NFAT) family 
of transcription factors (NFAT1-5) (Table 1.3), although a number of other calcineurin 
substrates have also been identified. After dephosphorylation by calcineurin, NFAT 
shuttles from the cytosol into the nucleus, where it acts as a transcription factor. (Rusnak 
& Mertz 2000; Jain et al. 1993)  
Table 1.3 NFAT family members.  
Name Alternate 
names 
Expression Pattern Knockout phenotype 
NFAT1 
 
NFATc2 
NFATp 
Immune cells, olfactory 
cells, endothelial cells, 
skeletal muscle, 
chondrocytes, adipocytes 
Immune hyperactivation and 
allergic responses  
Suppression of chondrogenesis 
(NFAT1+2 double knockout = 
failure of T cell activation and 
immune response) 
NFAT2 
 
NFATc1 
NFATc 
Immune cells, endothelial 
cells, skeletal muscle 
 
Lethal failure of cardiac 
morphogenesis 
Defects in thymic development 
and T cell activation in RAG1-/- 
chimeras 
NFAT3 
 
NFATc4 Embryonic: vascular 
precursor 
Endothelial cells, 
adipocytes 
No apparent defects 
(NFAT3+4 double knockout = 
lethal vascular patterning 
defects) 
NFAT4 
 
NFATc3 
NFATx 
Embryonic: vascular 
precursor 
Immune cells, endothelial 
cells, skeletal muscle, 
keratinocytes 
Defects in thymic development 
and hyperproliferation of 
lymphocytes 
NFAT5 
 
TonEBP 
OREBP 
Immune and tumor cells Unknown 
 
In T-cells, nuclear NFAT transactivates genes that are required for T-cell activity, 
such as IL-2 and the IL-2 receptor (Hogan et al. 2003). In other cell types, NFAT is 
responsible for cell-specific gene transactivation or repression. For example, calcineurin 
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is highly expressed in neuronal tissue and plays a role in neuronal plasticity and memory 
consolidation (Mansuy 2003). The role of calcineurin in the vasculature is an active and 
important area of research (Nilsson et al. 2008). Calcium signaling is highly regulated in 
the myocardium. In embryonic cardiovascular development, calcineurin signaling is 
involved in the migration of the myocardial precursors and the formation of the heart 
valves (Chang et al. 2004). Post-natally, the calcineurin-NFAT pathway appears to 
dichotomously regulate heart size and hypertrophic responses as well as exert a protective 
effect on the heart (Molkentin 2004). Specific loss of calcineurin in the heart results in 
mice with smaller hearts at baseline that are also refractory to hypertrophic growth (Frey 
& Olson 2003). This and other studies indicate the potential for targeting calcineurin 
signaling for developing therapies for hypertrophic cardiomyopathy (Frey & Olson 2003).   
 
Calcineurin signaling in tumorigenesis  
As the calcineurin-NFAT pathway regulates a variety of physiological tissue-
specific cellular effects, it similarly has been found to be dysregulated in cancers with a 
multitude of effects. There are five NFAT family members with varying degrees of 
redundancy and specificity in their downstream effects (Table 1.3). NFAT1 and 2 have 
similar DNA binding domains and are mostly functionally redundant. NFAT3 and 4 also 
share similar roles (Crabtree & Olson 2002). Unlike other NFAT proteins, NFAT 5, is 
not regulated by calcineurin (Mancini & Toker 2009). Dysregulation of NFAT expression 
or signaling has been found in various cancers and reflects its tissue-specific functions. 
Consistent with its role in the immune system, activated nuclear NFAT2 has been found 
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in cases of hematological malignancies such as Burkitts lymphoma, diffuse large cell B 
cell lymphoma, and T cell lymphomas, and responds to calcineurin inhibition (Mancini & 
Toker 2009). Additionally, NFAT2 has been found to be overexpressed in pancreatic 
cancers. Expression of NFAT1 in breast cancer promotes invasion and migration through 
increased transactivation of the direct NFAT target, COX-2. Furthermore, the 
calcineurin-independent NFAT5 has also been shown to be an effector in integrin 
mediated migration but not invasion in breast cancer, demonstrating multiple and 
complex roles of NFAT family members in tumorigenesis (Jauliac et al. 2002).    
 
Calcineurin signaling in tumor angiogenesis 
The calcineurin pathway in the tumor microenvironment plays a critical role in 
tumor angiogenesis. Calcineurin is highly expressed in endothelial cells and is 
downstream of VEGF signaling. Activation of VEGFR2 by its ligands increases 
intracellular calcium, which activates calcineurin and subsequently causes NFAT nuclear 
localization. In endothelial cells, NFAT promotes the transcription of angiogenesis 
responsive genes, such as cyclooxygenase-2 (COX-2), E-selection, and tissue factor 
(Hesser et al. 2004). The physiological relevance of the calcineurin-NFAT pathway in 
tumor angiogenesis is illustrated in the Down Syndrome (trisomy 21) population. 
Individuals with Down Syndrome have an extra copy of chromosome 21 and are 
protected from up to 90% of solid tumors when compared to age-matched controls (Yang 
et al. 2002), suggesting the increased expression of tumor suppressor genes. Alternatively, 
as solid tumors require angiogenesis for progression, overexpression of anti-angiogenic 
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regulators can tip the angiogenic balance against the growth of tumor vessel, halting solid 
tumor growth. Indeed, chromosome 21 encodes DSCR-1, dual specificity tyrosine-
phosphorylation-regulated kinase 1A (DYRK-1A), and PCP-4, which are three negative 
regulators of calcineurin. A mouse model of Down Syndrome also demonstrated 
decreased tumor growth in a transplantable tumor model (Baek et al. 2009). Modest 
overexpression of just one gene that negatively regulate calcineurin, DSCR-1, from three 
alleles as opposed to two, was sufficient to inhibit calcineurin activity in endothelial cells, 
resulting in decreased tumor growth and tumor angiogenesis. In light of this work, it is 
clear the calcineurin pathway is a critical determinant in tumor angiogenesis and 
inhibition by the endogenous protein DSCR1 can be potentially exploited to develop new 
anti-angiogenic therapies for solid cancers. Furthermore, studies of trisomy 21 highlight 
additional molecules such as DYRK-1A and PCP-4, also involved in the negative 
regulation of calcineurin signaling, that may yield potential anti-angiogenic therapies.    
 
Cyclosporin A and Tumorigenesis 
Pharmacological calcineurin inhibitors have been used clinically for decades as 
immunosuppressive drugs. Cyclosporin A (CsA), a cyclic fungal peptide, was first 
identified in 1970s as a potent T cell inhibitor, and subsequently the entire calcineurin-
NFAT pathway was elucidated based on its interactions (Rusnak & Mertz 2000; 
Clipstone & Crabtree 1992; Jain et al. 1993). As a potent immunosuppressant, CsA is 
used primarily in organ transplant patients to prevent graft rejection, but is also used for 
dermatological, ocular, and various autoimmune conditions. Within a cell, CsA 
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complexes with intracellular cyclophilins, a family of peptidy-propyl isomerases (PPI). 
When CsA is bound to the cyclophilin family member cyclophilin A, it forms a complex 
that sits at the substrate docking site of calcineurin, acting as a competitive inhibitor 
(Rusnak & Mertz 2000; Huai et al. 2002). Binding of CsA to other cyclophilins does not 
affect calcineurin activity, but is responsible for calcineurin-independent effects of CsA.  
Based on the positive role of calcineurin signaling in tumor angiogenesis, it would 
be reasonable to assume that use of CsA, a calcineurin inhibitor, would decrease solid 
tumor incidence. In contrast, there is a significant increase in the incidence of solid 
tumors in the organ transplant population who are on long-term CsA therapy when 
compared to aged matched controls. This increase in cancer risk is selective, with an 
increase in virally associated lymphomas and leukemia, and more prominently, skin 
cancers. Depending on the study, CsA therapy increases the risk of developing squamous 
cell carcinomas by 65-250 times compared to the general population, followed by basal 
cell carcinomas and melanomas (Kauffman et al. 2006). While non-transplant associated 
squamous cell carcinomas and basal cell carcinomas can be fatal if left untreated, they 
generally present as a slow growing tumors that are amenable to surgical excision and 
have a good prognosis. CsA-associated skin cancers, however, are more locally invasive, 
with much greater metastatic potential and a poorer prognosis (Dantal et al. 1998; Dantal 
& Soulillou 2005). 
This increase in cancer incidence after long-term CsA therapy is at odds with its 
role as a calcineurin inhibitor. Since CsA is a potent immunosuppressant, it was assumed 
that the increased cancer risk with CsA treatment was due to loss of immunosurveillance. 
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However, loss of immunosurveillance is not sufficient to account for the significant 
increase in tumorigenesis. Rapamycin, also an effective immunosuppressant used for 
organ transplants, is not associated with increased cancer risk, and actually has been 
shown to decrease tumor growth in some models (Guba et al. 2002). Additionally, CsA 
treatment has been shown to promote tumorigenesis in an immune-independent manner. 
In athymic nude mice and SCID mice, which lack functional B and T cells, CsA 
treatment still promotes the growth of subcutaneous xenograft tumors (Hojo et al. 1999). 
Several studies have investigated the mechanisms of CsA-associated tumorigenesis and 
are discussed in the following sections.  
 
CsA treatment and immunosuppression 
Cancers are often referred to as “wounds that never heal,” and the inflammatory 
contribution of immune cells to tumorigenesis is appreciated as a major regulator of 
tumor progression (Dunn et al. 2002), both in promoting and inhibiting cancer 
progression. The theory of immunosurveillance, first elaborated by Burnet and Thomas in 
1957 (Burnet 1957; Burnet 1970), depicts the immune system as anti-carcinogenic, 
recognizing cancer cells as “non-self” to be destroyed. Cancer cells, by their very nature, 
have escaped the normal constraints of their role in a multi-cellular organism, and are 
genetically and phenotypically different from normal cells. These differences allow for 
immunological recognition, which preludes their destruction by the adaptive immune 
system (Dunn et al. 2004). Additionally, infections by specific viruses such as human 
papilloma viruses, hepatitis B and C viruses, and herpes viruses, can elevate the risk of 
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associated cancer, especially if the infection is chronic and unresolved (Moore & Chang 
2010). Loss of immunosurveillance, as in the context of acquired immunodeficiency 
syndrome (AIDS) and various congenital defects, also elevates the risk of cancers (Gatti 
& Good 1971; Simard et al. 2011). Since calcineurin is important for T-cell activation, 
systemic CsA therapy results in profound immunosuppression. While CsA treatment in 
immunodeficient mice has been shown to promote tumorigenesis (Hojo et al. 1999), it 
does not absolutely exclude the contribution of CsA-induced immunosuppression to 
tumorigenesis. The importance of immunosuppression in CsA and cancer risk is 
highlighted by the elevated risk of virally-associated lymphoproliferative disorders 
(Dantal & Soulillou 2005) in transplant patients. Furthermore, viral load of human 
papilloma virus (HPV), which is associated with skin cancer risk, has been found to be 
elevated in individuals on CsA therapy (Harwood et al. 2000). The causative contribution 
of HPV to CsA-associated skin cancers, as it stands, is currently only correlative. The 
high association of HPV presence with CsA-associated cancers may be a direct cause-
and-effect, or two separate and unrelated manifestations of CsA treatment. More studies 
are required to elucidate the relationship between HPV infection, immunosuppression, 
and CsA-associated cancers. 
 
CsA treatment and TGF-β 
One of the hallmarks of CsA-associated cancers is the markedly increased 
invasiveness and high metastatic potential of these normally indolent tumor subtypes. 
The first study investigating the tumorigenic effects of CsA explored its role as a 
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metastatic promoter. CsA treatment in a transformed tumorigenic cell line induced an 
invasive phenotype in vitro and increased metastasis in vivo. This was associated with 
increased TGF-β production from tumor cells.  TGF-β has a double-edged effect on 
tumorigenesis; it suppresses cell proliferation and promotes differentiation, potentially 
halting tumor initiation, but it also promotes epithelial-to-mesenchymal 
transdifferentiation (EMT), which increases tumor invasion and cancer spread. Therefore, 
TGF-β acts as a tumor suppressor early on in tumor progression and a tumor promoter at 
later stages. In transformed malignant cells, CsA-induced TGF-β signals in a paracrine or 
autocrine manner to increase migration and invasion. CsA-induced TGF-β was also 
responsible for increased tumor metastasis in vivo, which was reduced to baseline with 
TGF-β neutralizing antibodies (Hojo et al. 1999). In a xenograft squamous cell carcinoma 
model, CsA-induced TGF-β caused EMT in tumor cells, marked by decreased E-cadherin 
and increased N-cadherin, vimentin, snail, twist, fibronectin, and α-SMA (Walsh et al. 
2011). In addition to promoting metastasis in mouse models of cancer, CsA-induced 
TGF-β contributes to nephrotoxicity and gingival hyperplasia, also side effects of CsA 
therapy (Naesens et al. 2009; Chung & Fu 2013). While TGF-β signaling can regulate 
NFAT activity, it is not entirely clear whether CsA induces TGF-β through calcineurin-
NFAT inhibition or by a calcineurin-independent mechanism.  
 
CsA treatment and cell proliferation 
In addition to promoting metastasis, CsA has also been shown to increase cell 
proliferation through Ras activation in renal carcinoma cells in vitro. By inhibiting 
24 
 
carabin, a negative regulator of Ras, CsA treatment results in greater Ras activity, 
offering an explanation for the rapid tumor growth seen in CsA-associated tumors (Datta 
et al. 2009). CsA has also been shown to increase cell proliferation in non-transformed 
cells. Gingival hyperplasia resulting from CsA treatment is thought to be due to a 
combination of TGF-β production and fibroblast proliferation (Chung & Fu 2013). 
Additionally, CsA-induced nephrotoxicity is at least partially attributed to glomerular cell 
proliferation (O’Connell et al. 2012). There is little consensus in the literature on the 
mechanism by which CsA promotes cellular proliferation. Several studies in non-
transformed cells have demonstrated CsA can affect cell proliferation through a reactive 
oxygen species (ROS) mediated hepatocyte growth factor pathway (O’Connell et al. 2012) 
or through AKT activation (Han et al. 2010). It is therefore most appropriate to conclude 
that CsA’s effect on cell cycle is complex and likely affecting multiple pathways in a cell 
and context dependent manner.  
 
DNA damage 
UV rays are electromagnetic radiation with wavelength between 100-400nm and 
is invisible to the naked eye but is emitted from many sources, with solar UV 
representing the bulk of exposure to humans. UVA is a longer wavelength UV radiation 
that can penetrate deep into the skin, but does not cause severe cellular damage, although 
prolonged exposure results in photoaging. UVB, on the other hand, is a shorter 
wavelength UV that can penetrate into the upper dermal layers, and has sufficient energy 
to cause cellular damage, resulting in sunburns (Novarina et al. 2011). DNA will absorb 
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UVB energy, which causes adjacent thymidine bases to bond together into pyrimidine 
dimers. Left unrepaired, pyrimidine dimers will block transcription and replication, 
stalling RNA and DNA polymerases, and can lead to double-stranded DNA breaks. 
Pyrimidine dimers are repaired by the nucleotide excision repair (NER) pathway, a 
conserved DNA repair pathway which specifically addresses UV-induced DNA damage. 
Defects in the NER pathway lead to several diseases that predispose individuals to cancer 
and early aging (Novarina et al. 2011).  
Because CsA-associated tumors are predominately skin cancers, it had been 
suggested that CsA may also negatively affect the NER pathway. The first support for 
this hypothesis was seen in lymphocytes, where CsA treatment allowed UV irradiated 
cells to re-enter the cell cycle without removal of the DNA damage product (Kuschal et 
al. 2009; Ahlers et al. 1999). Further work in fibroblasts demonstrated that CsA 
downregulates two of the proteins involved in NER, XP-A and XP-G, and this effect was 
phenocopied by calcineurin knockdown (Kuschal et al. 2011). Lastly, CsA treatment 
potentiated the carcinogenic effect of UV as shown by an increased incidence of skin 
tumors in UV-irradiated mice on CsA therapy (Han et al. 2012). Taken together, these 
studies convincingly show that CsA is involved in skin tumor initiation in the setting of 
UV irradiation by amplifying the mutational potential of UV-induced DNA damage. 
 
Inhibition of apoptosis by CsA 
The inhibitory effect of CsA on calcineurin is mediated through its interaction 
with cyclophilin A, but CsA can also bind to other cyclophilin family members, resulting 
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in calcineurin-independent effects. The cellular functions of most cyclophilin proteins are 
poorly characterized, making it difficult to determine the calcineurin-independent 
outcomes of cyclophilin-cyclosporin interactions. The function of one cyclophilin protein, 
cyclophilin D, however, is very well characterized, as is its binding with CsA. This 
particular cyclophilin family member is localized to the mitochondria inner membrane 
and is a regulatory component of the mitochondrial permeability transition pore (MPTP) 
(Fig. 1.3.). 
 
Fig 1.3. Current model of the mitochondrial permeability transition pore 
(MPTP). Adapted from (Halestrap & Richardson 2014). The definitive structural 
identity of the MPTP is under investigation, but the latest proposed model consists of 
an outer pore formed by the voltage-dependent anion channel (VDAC), various 
members of the BCL-2 family, and hexokinase (HK). The inner pore consists of 
adenine nucleotide transporter (ANT), phosphate carrier (PiC), the c-subunit of the 
FoF1-ATP synthase, and cyclophilin D (CypD). Creatine kinase (CK) bridge the 
outer and inner pore. Other molecules such as translocator protein and protein kinase 
C may also be associated (not shown).  
 
The MPTP is a calcium and ROS responsive nonselective channel that, when 
open, releases mitochondrial contents into the cytosol. Opening of the MPTP propagates 
cytosol 
Intermembrane 
space 
Mitochondrial 
matrix 
outer 
membrane 
inner 
membrane 
BCL-2 family  
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the apoptotic cascade and also aids the removal of aged mitochondria. Cyclophilin D 
regulates the stimulus threshold required for MPTP opening (Halestrap 2009).  
Binding of CsA to cyclophilin D raises the stimulus threshold required for pore 
opening, thereby decreasing pore opening. During conditions that trigger cell death 
pathways, CsA decreases apoptosis by preventing mitochondrial content efflux. This 
calcineurin-independent effect of CsA on the mitochondria has been confirmed through 
studies with the non-immunosuppressive cyclosporin analog, NIM811, which 
preferentially binds to cyclophilin D (Waldmeier et al. 2002). The anti-apoptotic effect of 
CsA is consistent across cell types, and it is currently being investigated as a potential 
therapeutic agent to attenuate ischemia-reperfusion injury in cardiac tissue (Piot et al. 
2008). Considering evasion of apoptosis is a significant factor in tumorigenesis, the 
ability of CsA to raise the apoptotic threshold allows for precancerous cells that would 
otherwise be eliminated through cell death to survive.  
This carcinogenic effect of CsA has been demonstrated in keratinocytes, the cells 
of origin for epidermal squamous cell carcinomas, where CsA treatment decreased UV-
induced apoptosis in vitro. This was found to occur in a calcineurin-independent manner 
as only CsA and NIM811, but not FK506, an unrelated calcineurin inhibitor, decreased 
UV-induced apoptosis (Norman et al. 2010). CsA-mediated evasion of apoptosis after 
UV irradiation may potentiate skin cancer initiation, as CsA-associated cancers generally 
occur in sun exposed areas and in individuals with low skin pigmentation (Moosa & 
Gralla 2005).  
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ATF3 
Oncogenic Ras mutations, specifically H-ras, are found in 10-20% of skin cancers 
(Boukamp 2005). Additionally, hyperactive Ras (beyond physiological levels), through 
DNA damage response secondary to hyperproliferation, can induce irreversible cell cycle 
arrest and senescence (Di Micco et al. 2006). Defects in oncogene-induced senescence 
allows for propagation of cancer cells into an expanding tumor. Using H-ras transformed 
human keratinocytes xenografted into immunocompromised mice; a recent paper showed 
calcineurin expression is required for oncogene-induced senescence. Calcineurin 
knockdown by siRNA or inhibition by CsA or FK506 bypassed oncogene-induced 
senescence and resulted in large and poorly differentiated tumors. This previously 
undescribed calcineurin-mediated oncogene-induced senescence was found to occur 
through NFAT transrepression of activating transcription factor 3 (ATF3). ATF3 is a 
stress-induced transcription factor found to both positively and negatively regulate the 
cell cycle (Boyd & Yan 2006; Thompson et al. 2010), and in this study ATF3 was found 
to function as a negative regulator of p53. Loss of calcineurin, or suppression by CsA, 
removed this inhibition on ATF3 transcription, whose expression decreased p53 levels 
bypassing Ras-induced p53-mediated senescence (Wu et al. 2010). The significance of 
oncogene-induced senescence in cutaneous squamous cell carcinoma, however, is 
controversial as it has only been described in vitro, but not in in vivo murine models 
(Tarutani et al. 2003; Dajee et al. 2002). Therefore, while CsA and calcineurin are shown 
to regulate ATF3 and senescence in mice, future studies are required to determine its 
contribution to CsA-associated cancers in humans.  
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CHAPTER 2: CYCLOSPORIN A PROMOTES TUMOR 
ANGIOGENESIS AND ENDOTHELIAL CELL ACTIVATION IN A 
CALCINEURIN INDEPENDENT MANNER  
 
Introduction 
Cyclosporin A (CsA) has been commonly prescribed for post-organ transplant 
immunosuppression since 1983. A well-documented adverse event for patients on CsA 
containing immunosuppressive regimens is a vastly increased risk of malignancy (Dantal 
& Soulillou 2005; Euvrard et al. 2003). With improvements in the organ-transplant field 
over the last few decades, allograft recipients are living longer, and CsA-associated 
tumorigenesis is an important cause of morbidity and mortality in that population. Newer 
generation immunosuppressants such as rapamycin and FK506 are replacing CsA as 
transplant immunosuppressants due to decreased side effects such as renal toxicity and 
malignancy risk. Many transplant recipients, however, have had past exposure to CsA 
prior to medication adjustment or are still on CsA therapies due to prescriber preference. 
Delineating the mechanisms by which CsA promotes tumorigenesis is critical for 
management and prevention of this adverse drug effect and may provide a greater insight 
on the role of the calcineurin pathway in cancer.  
It has long been assumed that CsA increases cancer risk through its 
immunosuppressive effects, leading to the loss of immunosurveillance, and escape of 
transformed tumor cells from immunoediting (Dunn et al. 2002). This hypothesis is 
supported by the fact that virally induced leukemias and lymphomas are found among 
CsA-associated malignancies (Durnian et al. 2007). However, the use of other equally 
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effective immunosuppressants for organ transplant patients, such as FK506 or rapamycin, 
is not associated with a similar cancer risk (Kauffman et al. 2006). Additionally, CsA 
treatment of immunocompromised mice promotes tumor growth and progression (Hojo et 
al. 1999), suggesting that at least one mechanism of CsA-induced tumorigenesis is 
independent of immunosuppression. 
There are several known pathways through which CsA can promote 
tumorigenesis discussed in detail in Chapter 1 and summarized in Figure 2.1. With the 
exception of increasing the apoptotic threshold, the effects of CsA on tumorigenesis have 
been shown or assumed to occur through calcineurin inhibition. Calcineurin 
dysregulation has been found in cancer cells as well as in the tumor microenvironment. 
The role for the calcineurin pathway in mediating tumor angiogenesis has been well 
characterized (Baek et al. 2009; Yao & Duh 2004; Nilsson et al. 2008). The calcineurin-
NFAT pathway is downstream of VEGF receptor activation in endothelial cells and 
transactivates angiogenesis-responsive genes. Suppression of calcineurin activity by its 
endogenous inhibitor Down syndrome candidate region 1 (DSCR1) results in a 
significant decrease in tumor growth due to inhibition of tumor angiogenesis (Baek et al. 
2009; Hesser et al. 2004; Chan et al. 2005; Yao & Duh 2004; Iizuka et al. 2004), 
suggesting a potential role for calcineurin inhibitors as anti-angiogenic therapy. As a 
pharmacological calcineurin inhibitor, the pro-tumorigenic effect of CsA is inconsistent 
with the established role for calcineurin in tumorigenesis. Studies examining the ability 
of CsA to negatively regulate tumor angiogenesis in a manner similar to DSCR1 are 
31 
 
limited. We therefore sought to examine the potential effects of CsA on tumor 
vasculature.  
 
Figure 2.1. Overview of the known mechanisms of cyclosporin A on 
tumorigenesis. The pathway or factors directly affected by CsA are highlighted in 
yellow. Abbreviations: MPTP = mitochondrial permeability transition pore, NER = 
nucleotide excision repair, ATF3 = activating transcription factor 3, TGF-β 
=transformation growth factor β 
 
FK506, or tacrolimus, is another calcineurin inhibitor also used in post-organ 
transplant immunosuppression. Patients on FK506-containing immunosuppressive 
regimens experience significantly decreased rates of malignancy compared to patients on 
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CsA (Kauffman et al. 2006), suggesting CsA’s ability to promote tumorigenesis, at least 
in part, is calcineurin-independent.  
While CsA forms a calcineurin-inhibitory complex with the cyclophilin family 
member cyclophilin A (CypA), it may also bind to other intracellular cyclophilins and 
mediate calcineurin-independent effects. For example, when bound to cyclophilin D, CsA 
increases the apoptotic threshold (Halestrap 2009). Therefore, we wanted to investigate 
the role of CsA in the tumor microenvironment and determine whether these effects 
depend on calcineurin.  
Based on previous reports showing that CsA treatment promotes tumor 
angiogenesis in a colon cancer model (Guba et al. 2002), we expect that chronic CsA 
treatment will also increase tumor angiogenesis in a skin cancer model. In order to 
evaluate the effect of CsA on angiogenesis, we characterized the effect of CsA on solid 
tumor growth and angiogenesis in vivo and on endothelial cell proliferation and migration 
in vitro. To assess for the calcineurin-dependence of these effects of CsA on angiogenesis, 
we utilized endothelial cells with a genetic deletion of calcineurin as well as cyclosporin 
analogs and other small molecule calcineurin inhibitors.    
We show that chronic CsA treatment increases tumor growth in two separate 
mouse models of skin cancer with increased tumor microvessel density. Treatment of 
primary mouse endothelial cells in vitro with CsA results in increased proliferation and 
migration. CsA-induced endothelial cell activation is calcineurin-independent, as it still 
occurs following genetic deletion of calcineurin and is not seen following treatment with 
other calcineurin inhibitors. 
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Results 
 
Cyclosporin A treatment increases skin tumorigenesis in vivo 
Previous studies investigating the in vivo effect of CsA on tumor growth were 
conducted in diverse tumor types including renal and lung carcinoma models. However, 
patients on long-term CsA treatment predominantly have an elevated risk of skin cancers. 
Therefore, to study the effect of CsA on tumor angiogenesis in a cancer type most 
relevant to the patient population on CsA therapy, we examined these effects in a 
chemically induced mouse model of skin cancer and in mice allografted with murine 
melanoma cells. 
To model squamous cell carcinoma, we used a well-characterized two-step 
chemical carcinogenesis model (Abel et al. 2011; Verma & Boutwell 1980) that results in 
de novo skin cancers. This model involves the one time topical application of the tumor 
initiator 7,12-dimethylbenz[α]anthracene (DMBA), which causes DNA damage and the 
emergence of H-ras mutant keratinocytes in the epidermis, followed by twice weekly 
application of the tumor promoter 12-O-Tetradecanoylphorbol-13-acetate (TPA). With 
continual carcinogen treatments, oncogenic mutations accumulate in keratinocytes, 
resulting in premalignant papilloma growth (Fig. 2.2.A). These papillomas are benign, 
but have pathological features similar to squamous cell carcinoma, such as the expansion 
of the basal cell layer, nests of tumor cells, and keratin pearls. Over time, they may 
progress into invasive carcinomas, although this is dependent on the genetic background 
of the mouse (Kemp et al. 1993). In the mouse strain used here (C57/BL6), 40 weeks of 
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TPA treatment did not result in carcinoma conversion. However, chronic CsA treatment 
of these mice at the clinical dose of 10mg/kg five days a week resulted in a significant 
increase in the number of dermal papillomas (Fig 2.2.B). The number of large papillomas 
was also greater, although not significantly so, in CsA treated mice (Fig 2.2.C).  
 Because CsA also increases the incidence and progression of melanomas in organ  
 
Figure 2.2. Cyclosporin A (CsA) treatment increases skin tumorigenesis in vivo. 
(A) Hematoxylin and eosin staining of WT C57/BL6 mouse skin. The left image is of 
normal skin. The middle and right images are of DMBA-TPA induced skin 
papillomas 40 weeks after treatment initiation with arrows pointing to expansion of 
the basal cell layer and keratin pearls, respectively. Quantification of (B) total 
papilloma per mouse or (C) only large papillomas in mice treated daily with peanut 
oil (vehicle) or 10mg/kg CsA. Representative photos are shown on the right (B) with 
papilloma highlighted in red. N=5 per group. (D) Tumor growth over time of 
subcutaneous xenograft tumors in mice treated with vehicle or CsA. WT mice were 
pre-treated with CsA or vehicle for 14 days prior to tumor inoculation and maintained 
on drug for duration of study. Results are representative of three experiments, with 
n=3-5 per group. Error bars indicate SEM, and * P <0.05 for all experiments. 
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transplant patients (Euvrard et al. 2003), we investigated the tumorigenic effects of CsA  
on melanoma in the B16-F10 transplantable melanoma mouse model. Chronic CsA 
treatment in wild type mice with allografted B16-F10 melanoma cells increased tumor  
growth compared to untreated mice (Fig 2.2.D). These data show that CsA treatment in 
mice potentiates skin tumorigenicity in at least two in vivo models of skin cancer. 
 
Cyclosporin A increases tumor angiogenesis 
Expansion of solid tumors is in part limited by the growth of new blood vessels in 
the tumor. Since calcineurin inhibition by DSCR1 suppresses neoplastic angiogenesis, we 
wanted to study the effect of CsA in the tumor microenvironment. Its function as a 
calcineurin inhibitor should block VEGF signaling in endothelial cells, decreasing tumor 
angiogenesis. The increase in tumor growth seen with CsA treatment, however, is 
inconsistent with that hypothesis.  
Chemically induced dermal papillomas from mice treated with CsA or vehicle 
control were harvested and sectioned for histopathological analysis. Vessel-like structures, 
characterized by a conspicuous lumen lined with end-to-end elongated cells that feature 
flat thin nuclei, are easily distinguishable (Fig 2.3.A), and their distribution in the tumor 
is heterogeneous. Analysis based on the number of vessels per tumor shows a trend 
towards more total vessels per mouse (Fig. 2.3.B), but no difference in vessel number per 
tumor if tumor size is taken into consideration (Fig 2.3.C & D). In our hands, 
immunofluorescence of tumor sections with anti-CD31 and anti-VE-Cadherin antibodies, 
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specific markers of endothelial cells was unsuccessful due to a high degree of 
autofluorescence in the skin tissue.  
A major limitation of the DMBA-TPA carcinogenesis model is that while it 
accurately portrays skin tumor progression, the tumors generated have heterogeneous 
vessel distribution that is difficult to quantify. Differences between treatment groups may 
be obscured by the varied structure of this particular tumor tissue. Additionally, 
papillomas on the C57/BL6 genetic background, which is relatively resistant to 
carcinoma conversion, do not grow very large and may not provide sufficient hypoxic 
stimulus for angiogenesis. 
 
 
Figure 2.3. CsA treatment on tumor angiogenesis in the DMBA-TPA induced 
skin cancer model. (A) Representative H&E staining of DMBA-TPA induced skin 
papilloma. Black triangles indicate putative endothelial cells lining tumor vessels, and 
scale bars indicate 50µm. (B) Quantification of total vessels counted per mouse in 
each cohort, each dot represents a mouse. (C) Quantification of total vessels counted 
per tumor in each cohort, each dot represents a tumor. (D) Quantification of vessels 
stratified by tumor size in each cohort. 
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B16-F10 allograft melanoma tumors also demonstrated increased tumor growth 
when treated with CsA, so we also assessed the role of CsA in tumor angiogenesis in this 
model. Melanoma allograft tumors were harvested from mice maintained on CsA or 
vehicle therapy and frozen sections were immunostained with anti-CD31 antibody and 
Hoechst. Random low powered images of the tumors were taken (Fig. 2.4.A) and CD31 
positive units, vessel number, lumenized vessels, and large vessels (≥100µm) were 
counted and analyzed. We found an increase in CD31 positive units and total vessel 
number in tumors from mice that were treated with CsA (Fig. 2.4.B). There was no  
 
 
Figure 2.4. CsA treatment increase tumor angiogenesis in the B16-F10 allograft 
tumor model. (A) Representative immunofluorescence images of B16-F10 tumor 
sections stained with anti-CD31 (red) and Hoechst (blue), scale bars indicate 100µm. 
(B) Quantification of microvessel density, number and size. Microvessel density is 
quantified by the total number of CD31
+
 units in a high powered field (hpf), 
lumenized CD31
+
 structures and CD31
+
 structures measuring 100µm or longer are 
also counted. (C) Quantification of Evans blue dye in tumor tissue normalized to 
tumor weight. B16-F10 tumor-bearing mice were treated with either vehicle or CsA. 
Error bars indicate SEM, and * P <0.05 for all experiments.  
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significant change in the number of lumenized vessels, and only a small increase in the 
number of large vessels (≥100µm) in tumors from mice treated with CsA compared to 
vehicle (Fig. 2.4.B). The majority of the increased microvascular density found in CsA-
treated tumors consisted of small, short CD31
+
 structures. These findings where CsA 
treatment leads to an increase in small short vessels without affecting larger or lumenized 
vessels suggests that CsA may promote the early stages of tumor angiogenesis, which is 
marked by cell proliferation and sprout formation.  
It remains undetermined whether CsA has an effect on vessel maturation and 
leakiness. We sought to test the effect of CsA on tumor vessel permeability by injecting 
Evans blue dye into the systemic circulation, then quantifying its tissue distribution. 
There were no differences in tumor vessel permeability between groups (Fig. 2.4.C). 
However, there was high variation in each group, potentially obscuring subtle differences.  
 
Cyclosporin A treatment promotes endothelial cell activation in vitro 
To isolate the specific effects of CsA on the process of angiogenesis, we treated 
primary endothelial cells isolated from the lungs of adult mice with CsA. These 
microvascular endothelial cells are isolated using anti-CD31-conjugated magnetic beads 
and generally are 90-95% CD31
+
. CsA treatment of primary endothelial cells led to 
increased cell number over time (Fig. 2.5.A) with increased 5-bromo-2’-deoxyuridine 
(BrdU) incorporation (Fig. 2.5.B), a synthetic nucleotide whose incorporation into a cell 
indicates active DNA replication. We also assessed for apoptosis using terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), an apoptotic marker  
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Figure 2.5. Cyclosporin A potentiates endothelial cell proliferation and 
migration in vitro. (A) Cell numbers of endothelial cells with 0.25µM CsA or 
vehicle treatment. Results are representative from three experiments, with n=3 per 
group. (B) Representative images of endothelial cells treated with 0.25µM CsA, 
5ng/mL EGF or vehicle for 48 hours, pulsed with BrdU (red), and stained with 
Hoechst (blue). Quantification of BrdU
+
 cells is shown in the graph. (C) 
Quantification of TUNEL
+ 
endothelial cells after treatment with vehicle or CsA for 
72 hours or doxorubicin (Dox) for 24 hours, n=5 per group. (D) Representative 
images of endothelial cells migrating through a transwell filter with vehicle or 
0.25µM CsA treatment. Quantification of cells counted per hpf is shown on the 
bottom. FGF (100ng/ml) is used as a positive control. Results are representative of 
three experiments. (E) WT endothelial cells were treated with vehicle or CsA and 
then seeded onto Matrigel and images were taken 5.5 hours later. Error bars indicate 
SEM, and * P <0.05 for all experiments. n.s. = not significant. Scale bars in (B), (D), 
and (E) indicate 100µm. 
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which labels fragmented DNA, and found no difference in TUNEL staining between 
vehicle and CsA treated cells (Fig. 2.5.C). These data indicate that CsA increases 
endothelial cell proliferation.  
During the early stages of angiogenesis, endothelial cells migrate towards 
chemotactic gradients to form the nascent vessel before coalescing together to form a 
tube (Carmeliet 2000). To test the effect of CsA on endothelial cell migration, we pre-
treated endothelial cells with CsA for two hours and created a CsA gradient in the lower 
well of the Boyden chamber. We found more cells migrated through the transwell filter 
with CsA treatment (Fig. 2.5.D) after 4 hours. Lastly, we tested the effect of CsA on 
endothelial cell tube formation, an in vitro measurement of endothelial cell adhesion, 
migration, protease activity, and tubule formation. Endothelial cells were plated onto a 
Matrigel matrix, and over the next 4-12 hours they invade and coalesce together to form 
tube-like structures. CsA treatment had no effect on endothelial cell tube formation 
compared to control treated cells (Fig. 2.5.E). These data suggest that CsA promotes 
angiogenesis through proliferation and migration with little effect on adhesion and tube 
formation.  
 
Calcineurin inhibitors (CNI) have differential effects on endothelial cell activation 
The calcineurin pathway is found downstream of VEGFR2 signaling in 
endothelial cells, and its activity in these cells results in transactivation of pro-angiogenic 
genes like E-selectin, COX-2, and tissue factor (Armesilla et al. 1999; Hernández et al. 
2001). The endogenous calcineurin inhibitor DSCR-1 has been shown to inhibit 
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endothelial cell proliferation (Baek et al. 2009; Hesser et al. 2004; Chan et al. 2005; Yao 
& Duh 2004; Iizuka et al. 2004). It is therefore inconsistent that CsA, a potent calcineurin 
inhibitor, increases endothelial cell proliferation and migration. As a small molecule 
inhibitor, CsA may have additional effects independent of calcineurin inhibition.  
To test whether the endothelial cell phenotype induced by CsA is due to 
calcineurin inhibition, we compared the effects of CsA with those of two other 
calcineurin inhibitors. First, we made use of transgenic Dscr1 mice which express three 
alleles of the endogenous calcineurin inhibitor Dscr1, resulting in increased protein levels 
(Baek et al. 2009). There were fewer DMBA-TPA induced papillomas in transgenic 
Dscr1 mice compared to wild-type mice treated with CsA (Fig. 2.6.A). Additionally, CsA 
treatment of DSCR1 overexpressing endothelial cells increased cell proliferation (Fig. 
2.6.B) whereas DSCR1 overexpression by itself decreased cell numbers compared to 
wild type cells (Baek et al. 2009), suggesting separate and distinct underlying 
mechanisms by which these two calcineurin inhibitors act in endothelial cells. We also 
assessed the effects of the structurally dissimilar but functionally comparable small 
molecule inhibitor FK506, which is also used clinically as an immunosuppressant. 
Whereas CsA binds to cyclophilin A to inhibit calcineurin, FK506 instead binds to FK 
binding proteins and forms an independent but convergent calcineurin inhibitory complex. 
FK506 treatment of B16-F10 allograft tumor-bearing mice resulted in smaller tumors 
compared to CsA-treated B16-F10 allograft tumor-bearing mice (Fig. 2.6.C), consistent 
with the hypothesis that CsA promotes tumorigenesis in a calcineurin-independent 
manner. FK506 treatment decreased endothelial cell numbers and inhibited VEGF-
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induced migration in vitro when compared to CsA (Fig. 2.6.D&E) The differential effects 
seen with CsA and FK506 suggests these two molecules, despite both being calcineurin  
 
Fig. 2.6. Calcineurin inhibitors have opposing effects on tumorigenesis and 
endothelial cell activity. (A) Quantification of DMBA-TPA induced skin papilloma 
measured over time in Dscr1 transgenic (Tg) or WT mice treated with vehicle or CsA. 
(B) Proliferation of WT and Dscr1 Tg primary endothelial cells after treatment with 
vehicle or 0.25µM CsA. Cell numbers are counted every other day. (C) 
Quantification of B16-F10 melanoma tumor growth in WT mice in either control 
group, treated with 10mg/kg CsA or 0.15mg/kg FK506, tumor size is shown on the 
right. (D) Proliferation of WT primary endothelial cells after treatment with vehicle, 
0.1µM FK506, or 0.25µM CsA. (E) Quantification of endothelial cells migrating 
through a transwell filter in response to vehicle, 100ng/mL VEGF, and 0.1µM FK506 
or 0.25µM CsA. Error bars indicate SEM, and * P <0.05 for all experiments. 
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inhibitors, have separate effects. We expected that FK506, as a calcineurin inhibitor, 
would decrease endothelial cell numbers but instead found it had no effect on cell 
numbers when compared to the vehicle treated group. This result suggests a calcineurin-
independent action of FK506 on FK binding proteins, which are highly expressed in 
endothelial cells (Higgins et al. 2003) with poorly delineated functions, but its inhibition 
by FK506 may independently affect angiogenesis. FK506 is known to be a more potent 
calcineurin inhibitor than CsA (Woo & Propper 1990), and the concentration of FK506 
used in vitro was adjusted to account for this discrepancy. A dose-curve, however, was 
not performed and may further explain the differences. Taken together, these data are 
highly suggestive of a pro-angiogenic effect of CsA that occurs independent of 
calcineurin signaling.  
 
Cyclosporin A treatment activates endothelial cells in a calcineurin-independent 
manner. 
To investigate the effects of CsA treatment in absence of calcineurin, a transgenic 
mouse strain with a conditional calcineurin deletion was utilized. This transgenic mouse  
 
Figure 2.7. Adenovirus Cre infection in Calcineurin Bf/f (CnBf/f) endothelial cells (EC) 
results in the loss of calcineurin A protein. Western blot showing calcineurin A protein 
in endothelial cells without Adeno-Cre infection, or with Adeno-Cre infection at the 
indicated infection ratio and passage (P) number. Endothelial cells were infected at P1 
and Calcineurin B deletion was assessed by presence of calcineurin A protein at P2 and 
P6. 
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has loxP sites flanking the calcineurin B (CnB) gene, which is excised upon Cre 
recombinase administration. Without CnB, the catalytic calcineurin A subunit degrades.  
Primary lung endothelial cells were isolated from CnB
flox/flox 
mice and treated in vitro with  
adenovirus carrying Cre recombinase (Adeno-Cre). Upon infection with Adeno-Cre, 
calcineurin A protein is lost from endothelial cells within 1-2 passages and remains 
absent for up to four additional passages in vitro (Fig. 2.7.).  
 In agreement with our earlier pharmacologic data, CsA treatment in 
calcineurin-null endothelial cells increases cell numbers, comparable to its effect in wild 
type endothelial cells (Fig. 2.8.A&B). Calcineurin deletion in endothelial cells results in a 
near complete loss of migration through a transwell filter (Fig. 2.8.C&D). These data 
demonstrate that calcineurin is not required for the pro-proliferative phenotype induced 
by CsA in endothelial cells.   
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Fig. 2.8. Calcineurin is not required for cyclosporin A-induced endothelial cell 
proliferation and migration (A, B) Proliferation of uninfected (A) or adenovirus-
Cre infected (B) Calcineurin B
flox/flox
 (CnB
f/f
)
 
primary murine endothelial cells in the 
presence of 0.25µM CsA or vehicle alone. Cell numbers were counted every other 
day. (C, D) Representative images of uninfected (C) or adenovirus-Cre infected (D) 
CnB
f/f 
primary murine endothelial cells migrating through a transwell filter in 
response to 0.25µM CsA or vehicle alone. FGF is used as a positive control. 
Quantification of cells per high-powered field (hpf) is shown on the bottom. Scale 
bars indicate 100µm. Results are representative of two experiments, with n=3 per 
group. Error bars indicate SEM, and * P <0.05 for all experiments. 
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Discussion 
 
Our data show that chronic CsA treatment in vivo promotes skin tumorigenesis in 
two separate murine skin cancer models. This is accompanied by increased tumor 
angiogenesis with amplification in the number of short small vessels and minimal change 
in the number of large lumenized vessels. In vitro, CsA increases the proliferation and 
migration of primary endothelial cells. This occurs in a calcineurin-independent manner, 
as calcineurin-null endothelial cells responds to CsA in a manner similar to wild-type 
endothelial cells, and these effects were not seen with other calcineurin inhibitors.  
Considering the cancer profile associated with CsA therapy in transplant 
populations, it would be pertinent to use a skin cancer model to study this phenomenon in 
mice. Since CsA-associated cancers skew significantly towards squamous cell 
carcinomas (SCC), in vivo mouse models of SCC would be ideal for studying CsA’s 
effect on tumorigenesis. There are several in vivo SCC progression mouse models; the 
chemical carcinogenesis (DMBA-TPA) model described earlier in this chapter and UV 
irradiation of hairless/shaved mice (Gruijl & Forbes 1995). Additionally, genetic 
manipulation of p53 and Ras in the dermis, in combination with chemical carcinogens, 
has also been shown to produce SCC (Caulin et al. 2007; Zhang et al. 2005). Lastly, SCC 
xenografts, comprised of human SCC cell lines or H-ras overexpressing human 
keratinocyte grafts (Wu et al. 2010) have also been used to study skin cancer progression.  
Given the multi-stage nature of the DMBA-TPA skin carcinogenesis model and 
its similarity to human disease (Abel et al. 2011; Verma & Boutwell 1980), it was a 
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reasonable model to study the effects of CsA on cancer. CsA treatment in C57/Bl6 mice 
subjected to multiple rounds of topical carcinogens had more papilloma growth than 
vehicle treated mice. However, the genetic background of the mouse has a significant 
impact on cancer progression. In the C57/Bl6 mouse strain in our studies, these 
papillomas never converted to carcinomas nor grew very large, making it difficult to 
assess the angiogenic requirements of the tumors. It is also unclear whether the increase 
in papilloma number found in CsA-treated mice is due to increased angiogenesis or if it is 
a direct effect of CsA on keratinocytes, as CsA has also been shown to suppress cell 
death and DNA damage repair in DNA-damaged keratinocytes (Yarosh et al. 2005; 
Norman et al. 2010; Han et al. 2012). Although the cytochrome P450 isozyme 
responsible for converting DMBA from a prodrug to its more carcinogenic form DMBA-
DE is distinct and separate from the P450 isozymes which metabolize CsA (Gao et al. 
2005; Staatz et al. 2010), we cannot rule out a drug interaction between DMBA and CsA 
through the induction of P450 enzymes. It is also interesting to note that in our 
experiments, the number of papillomas per mouse increased steadily over time until week 
20, then remained relatively stable for the duration of the experiment (20 additional 
weeks) despite continued TPA administration, suggesting a limitation in papilloma 
numbers imposed by the initial number of DMBA transformed cells. Moreover, the tumor 
structure of the papillomas was heterogeneous, and randomly taken images showed high 
variation in vessel-like structures, making vessel density highly variable and 
quantification of angiogenesis difficult. 
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 Subcutaneous xenograft injections of the human squamous cell carcinoma cell 
line SCC-13 (Okano et al. 2000) resulted in high variability in tumor size within each 
group (data not shown), potentially obscuring any treatment effects.  Due to these 
limitations, we were not able to assess the effect of CsA on angiogenesis in this in vivo 
model of SCC.  
While transplant patients on CsA therapy have an increased risk of squamous cell 
carcinoma, they are also at elevated risk for basal cell carcinoma and melanoma. The 
B16-F10 allograft mouse model of melanoma is a well-characterized model for studying 
melanoma, angiogenesis, and metastasis (Ryeom et al. 2008; Nicolson et al. 1978). 
Therefore, we utilized the transplantable B16-F10 melanoma cells in an allograft tumor 
model to determine the effect of CsA on tumor angiogenesis. CsA treatment increased 
tumor angiogenesis as well as tumor size, which was consistent with our hypothesis. 
However, there are limitations to this model. The subcutaneous allograft injection of 
already transformed B16-F10 tumor cells into the mice allows for studying tumorigenesis 
only in the late progression stage, as tumor initiation and early progression is bypassed. 
Additionally, while B16-F10 allograft tumor model have been used by other groups to 
study metastasis, in our hands, this metastasis model showed high variability from 
experiment to experiment and could not be used to assess the effects of CsA on 
metastasis.  
To best understand whether CsA has a pro or anti-angiogenic effect on 
tumorigenesis, we used the clinically relevant dose of 10mg/kg CsA for our in vivo 
experiments, a comparable dose used for transplant patients. We did not, however, assess 
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the serum levels of CsA in the mice to compare to human populations. When used at this 
dose, CsA therapy consistently increased the number and size of solid tumor formation 
(Yajima et al. 2008; Guba et al. 2002) as well as tumor angiogenesis (Guba et al. 2002). 
In the B16-F10 allograft melanoma mouse model, CsA treatment had a specific effect on 
the quantity and phenotypic appearance of tumor vessels.  
 While neoplastic vessels are generally considered to be inferior conduits for 
nutrient and oxygen delivery compared to normal vessels, they are still able to meet some 
of the metabolic demands of the tumors. Although tumor vasculature varies depending on 
the tumor type, the microvessel density in most solid tumors has been shown to be 
correlated with greater tumor growth, decreased patient survival, and poorer prognosis 
(Hlatky et al. 2002).  
In the B16-F10 allograft melanoma model, the tumor vasculature consists of a 
mixture of immature and mature vessels, including lumenized larger vessels. CsA 
treatment increased the overall microvessel density of the tumors, which would raise the 
metabolic limit on the tumor cells imposed by vessel density. Additionally, CsA 
treatment resulted in a striking increase in small and short vessels, with little or modest 
change in the number of lumenized vessels or larger vessels. In a hypoxic tumor, 
increases in vessel density, even small and immature vessels, still aid in nutrient delivery.  
Due to technical limitations, we were unable to determine the effects of these 
additional small vessels on tumor and tissue perfusion. While we have shown by staining 
that there are increased vessel structures within the tumors, in vivo labeling of tumors 
with FITC-lectin or FITC-dextrin would be helpful to determine in vivo functional quality 
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of these vessels. Alternatively, Doppler ultrasound could be used to assess fluid/blood 
flow within the tumor, and tumor pO2 could be measured with an Eppendorf fine needle 
probe (Menon et al. 2003). While the time frame of our tumor model did not allow for 
metastasis, immature small vessels often show a paucity of pericytes and leakier cell to 
cell junctions compared to mature vessels and could promote increased tumor cell escape 
into the periphery. Future studies using metastatic cancer models could determine 
whether the aberrant tumor vessels induced by CsA treatment contribute to the metastatic 
potential of solid tumors.  
Because CsA treatment likely affects multiple signaling pathways in endothelial 
cells, we conducted our experiments using a low dose of CsA that fell within the pro-
proliferative range in order to best dissect the pro-angiogenic effects of CsA. Using this 
dose, we show that CsA-treated endothelial cells have greater proliferation and migration 
in vitro compared to vehicle treated cells, but no difference in tube formation in Matrigel. 
The tube formation assay is an in vitro model for the later stages of angiogenesis, such as 
adhesion, matrix invasion, and capillary tube formation. However, due to the short time 
frame and reduced growth factor conditions, endothelial cell tube formation does not 
accurately reflect changes in proliferation. These data suggest that CsA specifically 
affects the early stages of angiogenesis, especially endothelial cell proliferation and 
migration. Future characterization of protease production and activation, as well as cell 
surface receptors (adhesion molecules, VEGFR, Tie receptors) in endothelial cells would 
be helpful to further elucidate the specific angiogenic pathways affected by CsA.  
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Systemic CsA treatment results in drug accumulation in multiple tissues and cell 
types in addition to tumor and endothelial cells. Pericytes or vascular smooth muscle cells 
are important vascular regulators and are often abnormal in neoplastic vessels. While the 
effect of CsA on tumor-associated vascular smooth muscle cells is not known, previous 
studies have demonstrated that CsA can affect proliferation, adhesion, and cellular 
orientation of vascular smooth muscle cells (Garvey et al. 2010). Our study demonstrates 
a direct effect of CsA on endothelial cells in vitro but does not rule out the potential 
involvement of other cell types such as vascular smooth muscle cells. Staining of tumors 
from CsA-treated mice for vascular smooth muscle markers in combination with 
permeability studies and in vitro characterization of vascular smooth muscle cells after 
CsA treatment in co-culture experiments with endothelial cells or tumor cells may help 
clarify the contribution of vascular smooth muscle cells to the CsA-associated 
angiogenesis.  
While we are studying the effect of CsA in the context of tumor angiogenesis, it 
has been investigated by other groups in nonmalignant pathological angiogenic settings, 
although the results are varied and appear to be dose-dependent. Generally, high doses 
(>5µM) of CsA in vitro has been found to be anti-angiogenic. One study found that CsA, 
in combination with the antifungal drug itraconazole, is selectively toxic to endothelial 
cells (Nacev & Liu 2011). The same group found that CsA was toxic to human umbilical 
vein endothelial cells in a calcineurin-independent manner, presumably through binding 
to cyclophilins (Nacev et al. 2011). In a mouse model of neovascular (wet) macular 
degeneration, both CsA and a non-immunosuppressive analog N-MeVal-4-CsA 
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decreased choroidal neovascularization (Nacev et al. 2011). Low doses (<0.5-1µM) of 
CsA, on the other hand, have been shown to exert a cytoprotective effect on endothelial 
cells in vitro by increasing VEGFR2 levels (Alvarez-Arroyo 2002). If CsA has dose-
dependent cellular effects on endothelial cells, there must be a combination of 
independent pathways affected, one of which is the inhibition of the angiogenic 
calcineurin-NFAT axis. Therefore, in order to produce the pro-angiogenic effects 
observed, CsA must evoke an alternative, activating pathway in endothelial cells.  
Most studies involving CsA assume that the effects seen occur in a calcineurin-
dependent fashion. In our experiments, the pro-proliferative effects induced by CsA in 
endothelial cells are at odds with the known effects of calcineurin inhibition in this cell 
type. Therefore, we hypothesized that these events occur in a calcineurin-independent 
manner. In agreement with this, other CNIs have dissimilar effects on tumorigenesis and 
endothelial cell activity when compared to CsA. It is important to note, however, that 
calcineurin inhibition by DSCR1 and FK506 in in vivo murine tumor models is not 
limited to endothelial cells but extends to other cell types. Therefore, we also assessed the 
effect of different CNIs on endothelial cells in vitro. Additionally, while we used a lower 
concentration of FK506 for in vitro studies to partially reflect its greater potency (Kino et 
al. 1987), ideally a dose curve would be more informative.  
We found that calcineurin loss in endothelial cells had no effect on the ability of 
CsA to increase proliferation; therefore, we concluded that CsA promotes pro-angiogenic 
behavior in endothelial cells in a calcineurin-independent manner. However, this does not 
necessarily mean that calcineurin inhibition by CsA does not have a significant effect in 
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endothelial cells, as it still occurs regardless of off-target effects and likely explains the 
toxicity seen at high doses. 
In summary, our data show that CsA increases tumor growth and angiogenesis in 
vivo, and it promotes endothelial cell proliferation and migration in vitro in a calcineurin 
independent manner. In chapter 3, we will explore potential calcineurin-independent 
pathways stimulated by CsA treatment that may be responsible for the pro-proliferative 
and migratory effects seen in endothelial cells.  
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CHAPTER 3: CYCLOSPORIN A INCREASES ENDOTHELIAL 
CELL ACTIVITY THROUGH MITOCHONDRIAL REACTIVE 
OXYGEN SPECIES 
 
Introduction 
 
Our studies indicate that cyclosporin A (CsA) treatment increases tumor growth 
and angiogenesis in a mouse model of skin cancer. CsA treatment of endothelial cells in 
vitro increases proliferation and migration. These CsA-induced endothelial cell effects 
occurred in a calcineurin-independent manner, as CsA still affects calcineurin-null cells 
in a similar manner. Furthermore, treatment with other calcineurin inhibitors does not 
recapitulate this phenotype. Therefore, we investigated the underlying mechanism of 
CsA-induced endothelial cell activation in the absence of calcineurin.  
CsA is a fungal cyclic decapeptide with a high affinity for a family of intracellular 
poly-propyl-isomerases (PPI) called cyclophilins (Hemenway & Heitman 1999). This 
family of sixteen proteins catalyzes the cis to trans isomerization reaction in folding 
proteins. They act mostly as chaperone proteins and are implicated in both physiological 
and pathological processes (Wang & Heitman 2005). CsA binds to the cyclophilin family 
member cyclophilin A and forms a calcineurin-inhibitory complex, which occupies the 
substrate docking site and competitively displaces calcineurin substrates such as NFAT 
from docking and being dephosphorylated. The selectivity of this CsA-cyclophilin A 
complex for calcineurin inhibition is purely by structural chance, as neither CsA or 
cyclophilin A alone affects calcineurin activity (Hemenway & Heitman 1999). The 
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cellular roles of the other cyclophilins are not well defined, and the calcineurin-
independent effects of CsA binding to these cyclophilin proteins are not well known.  
The binding of CsA to cyclophilin D, a mitochondrially targeted PPI family 
member, has been well characterized (Friberg et al. 1998). Cyclophilin D is a part of the 
mitochondrial permeability transition pore (MPTP), a large calcium-responsive complex 
spanning the mitochondrial inner and outer membrane.  
The structural components of the MPTP is a subject of debate and the latest 
proposed model is illustrated in Figure 1.3; the voltage-dependent anion channel (VDAC) 
has been proposed as the outer membrane subunit and either the adenosine nucleotide 
translocase (ANT) or the mitochondrial phosphate carrier (PiC) have been proposed as 
the inner mitochondrial membrane subunit (Halestrap 2009). Hexokinase and translocator 
protein (TSPO, also known as peripheral benzodiazepine receptor) are also thought to be 
part of the MPTP (Brenner & Moulin 2012). Genetic deletions of these various 
components, however, does not result in mitochondrial permeability phenotypes, 
(Brenner & Moulin 2012), illustrating the controversy of the MPTP identity. Most 
recently, the c-subunit ring of the ATP synthase is highlighted as the putative inner 
mitochondrial membrane channel portion of the MPTP (Alavian et al. 2014). The 
structural identity of the MPTP remains an active area of research, and only cyclophilin 
D is agreed upon as an obligatory pore component.  
Despite the ambiguity of MPTP structural identity, its function is well known. 
The MPTP is triggered to open by mitochondrial matrix calcium and its sensitivity to 
calcium-induced opening can be affected by multiple factors. Stressors, such as apoptotic 
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stimulus, low ATP (Crompton 1999), UV irradiation (Norman et al. 2010), high pH, and 
high mitochondrial reactive oxygen species (ROS) increases the sensitivity of the MPTP 
to calcium-induced opening. Opening of the MPTP leads to equilibration of 
mitochondrial contents such as ROS, calcium, and other small molecules (<1.5kDa) 
across the mitochondrial membranes. This subsequently results in  mitochondrial osmotic 
imbalance and swelling (Halestrap 2009).  
The MPTP is believed have multiple physiological functions. As mitochondria 
age, mutations accumulate in the mitochondrial DNA, which encodes components of the 
electron-transport chain. Over time, the mitochondrial bioenergetic circuit becomes 
progressively uncoupled, leading to elevated ROS production, ion imbalances, and low 
ATP:ADP ratio. These signals can promote MPTP opening, which then causes 
destruction and removal of the unhealthy mitochondria (Wallace 2005). This process 
selectively removes old or unhealthy mitochondria from a cell. If occurring on a more 
widespread, cell-wide scale, it can also contribute to cell death. In those incidences, 
Bax/Bad megachannels can form on the swollen mitochondria, leading to cytochrome c 
release as part of the apoptotic cascade. 
Cyclophilin D plays a central role in regulating MPTP opening. Loss of 
cyclophilin D raises the stimulus threshold required to open the pore. CsA treatment 
phencopies cyclophilin D deletion and also results in decreased pore opening in response 
to stimulus. It’s not entirely clear how CsA binding to cyclophilin D affects its regulation 
of the MPTP, but it may occur through inhibition of the catalytic PPI activity of 
cyclophilin D (Halestrap & Davidson 1990), which has been shown to be important in 
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MPTP opening (Machida et al. 2006). CsA treatment consistently increases the apoptotic 
threshold of cells, and this off-target effect of CsA has been exploited experimentally to 
investigate mitochondrial function and apoptosis. Since mitochondrial content efflux is a 
major component of ischemia-perfusion injury, inhibition of the MPTP by CsA in 
cardiomyocytes decreases the severity of myocardial damage and is currently being 
investigated as potential therapy for myocardial infarction (Piot et al. 2008).  
Though CsA treatment decreases MPTP opening, the downstream effects on 
mitochondrial biology and specifically ROS levels appear to be context-dependent. 
Maintaining pore closure in the presence of an apoptotic stimulus impedes the release of 
mitochondrial ROS. For example, CsA treatment decreases the efflux of mitochondrial 
ROS in keratinocytes in response to UV irradiation (Norman et al. 2010). CsA treatment 
in non-apoptotic conditions, however, leads to increased cellular ROS levels (O’Connell 
et al. 2012; Longoni et al. 2001; Krauskopf et al. 2005). 
The mitochondria is a major producer of endogenous ROS as it is a byproduct of 
the electron transport chain (Adam-Vizi & Chinopoulos 2006). Endogenous ROS can 
also be generated through specific enzymatic processes such as the NAD(P)H oxidase, 
found in phagocytotic cells, endothelial cells, and smooth muscle cells (Touyz & Briones 
2011).  
In the body, ROS participates in the inflammatory response to neutralize 
pathogens. They are also involved in the pathogenesis of many conditions such as 
diabetes, atherosclerosis, and cancer (Bartosz 2009). ROS and other free radicals were 
initially shown to be damaging to cellular components due to their unstable atomic 
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structure, which causes protein and lipid oxidation and DNA damage. More recently, 
however, ROS have also been shown to act as a signaling molecule at low levels (Bartosz 
2009) and can affect a number of cellular processes, including mitogenic pathways 
(Finkel 2011). In the circulatory system, ROS and the closely related molecules reactive 
nitrogen species (RNS) are potent modulators of vascular tone (Yung et al. 2006; Maulik 
& Das 2002). Therefore, endothelial cells are very sensitive to changes in ROS and RNS. 
These compounds also affect endothelial cell junctions, which in turn alter vascular 
permeability (Monaghan-Benson & Burridge 2009). Furthermore, ROS signaling has also 
been shown to affect other processes such as angiogenesis by promoting endothelial cell 
migration and proliferation (Maulik & Das 2002; Ushio-Fukai 2006). 
We have shown that CsA treatment of endothelial cells promotes proliferation and 
migration in a calcineurin-independent manner. CsA is known to induce a strong 
calcineurin-independent effect by binding to the mitochondrially located cyclophilin D. 
Mitochondrial contents such as reactive oxygen species can trigger a variety of signaling 
pathways in the vasculature, including pro-angiogenic effects. Therefore, we hypothesize 
that CsA exerts a pro-proliferative and migratory effect in endothelial cells by stimulating 
the production of mitochondrial ROS. 
Here we show that treatment of endothelial cells with the non-immunosuppressive 
cyclosporin analog NIM811 phenocopies the effects of CsA. Furthermore, CsA treatment 
increases mitochondrial ROS levels and is associated with an increase in mitochondrial 
membrane potential. Antioxidant co-treatment with CsA abrogates the pro-proliferative 
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and migratory effects induced by CsA in vitro and decreases CsA-induced tumor growth 
in vivo.   
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Results 
 
Cyclosporin A increases endothelial cell proliferation and migration via its interaction 
with cyclophilins 
We showed previously that CsA is able to promote proliferation and migration of 
endothelial cells in the absence of calcineurin. Since CsA is not known to have 
cyclophilin-independent effects, we speculated that this calcineurin-independent effect of 
CsA is derived from its binding with other cyclophilin proteins. To test this hypothesis, 
we utilized NIM811, a non-immunosuppressive cyclosporin analog that is unable to bind 
calcineurin, but has similar binding profiles to cyclophilin proteins as CsA. In a manner 
similar to CsA, NIM811 interacts with the well-characterized cyclophilin D and it is often 
used as a research tool to study cyclophilin D and MPTP biology.  
Using WT endothelial cells, we compared the effect of NIM811 to CsA on 
endothelial proliferation. Dose-response proliferation curves for both drugs were bell-
shaped (Fig. 3.1A) after six days of treatment; low concentrations of CsA or NIM811 
(10nM – 1µM) increased endothelial cell numbers whereas higher concentrations (≥1µM) 
decreased cell numbers. Treatment with low concentration of either NIM811 or CsA 
increased endothelial cell growth over time compared to vehicle treated controls (Fig. 
3.1B). Furthermore, both CsA and NIM811 increased endothelial cell migration through 
a transwell filter (Fig. 3.1C). The comparable growth and migratory phenotypes 
following CsA and NIM811 treatment suggest that both molecules affect a common 
pathway. 
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Fig. 3.1. CsA and NIM811 promote endothelial cell proliferation and migration 
in vitro. (A) Proliferation of primary murine endothelial cells in response to 
increasing concentrations of CsA or NIM811. Cell numbers were counted after 6 
days of treatment, n=3. (B) Proliferation of endothelial cells treated with 0.25µM 
CsA, 0.1µM NIM811, or vehicle. Cell numbers were counted every other day. * P 
<0.05 (between vehicle and CsA, and between vehicle and NIM811). Results are 
representative of two experiments, n=3 per group. (C) Representative images of 
endothelial cells migrating through a transwell filter in response to 0.25µM CsA, 
0.1µM NIM811 or vehicle alone. Quantification of cell numbers per high-powered 
field (hpf) is shown below. Results are pooled from two experiments. Error bars 
indicate SEM, and * P <0.05 for all experiments. Scale bars indicate 100µm. 
 
 
Cyclosporin A treatment increases mitochondrial ROS  
Mitochondrial-derived ROS have been demonstrated to affect a number of 
cellular processes including cell growth (Hamanaka & Chandel 2010) and adhesion 
(Zhang & Gutterman 2007). We hypothesize that CsA treatment leads to an increase in 
mitochondrial ROS, leading to the observed endothelial cell changes. The exact effects of 
CsA on ROS are still unclear and may reflect differential MPTP activity in apoptotic vs. 
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non-apoptotic contexts. Therefore, we sought to determine the effects of CsA on 
mitochondrial ROS in our experimental model. 
Cellular ROS was measured using the commonly used ROS indicator DCFDA, a 
broad nonspecific indicator of multiple reactive oxygen species. We found endothelial 
cells treated with CsA showed no difference in DCFDA staining when compared to 
vehicle treated cells (Fig. 3.2A).  
While we expected to see an increase in cytosolic ROS following CsA treatment, 
we hypothesized that the levels of ROS induced by the concentration of CsA we used 
was low and non-damaging. Routinely used to measure the oxidative burst found in 
neutrophils and macrophages, DCFDA may not have the sensitivity to detect the low 
level of ROS generated by CsA in our system (Gomes et al. 2005). Additionally, the use 
of DCFDA for the detection of overall oxidative stress has been undermined by its 
inability to detect specific ROS (Myhre et al. 2003), such as H2O2 (in low peroxidase 
contexts). To investigate the effect of CsA specifically on mitochondrial ROS, we stained 
live cells with Mitosox, a mitochondrial targeted superoxide detector that fluoresces upon 
superoxide binding and is a sensitive and specific indicator of mitochondrial superoxide 
levels (Robinson et al. 2006), which can converted to the membrane permeant and 
angiogenic H2O2 (Urao et al. 2013; Boveris & Cadenas 2000). When compared to 
vehicle-treated cells, endothelial cells treated with CsA showed increased Mitosox 
staining as detected by flow cytometry (Fig. 3.2B). Furthermore, endothelial cells treated 
with NIM811 but not FK506 showed increased Mitosox staining when compared to 
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vehicle-treated controls (Fig. 3.2C). These results are consistent with our hypothesis that 
CsA increases mitochondrial ROS in a calcineurin-independent manner.  
 
 
Fig. 3.2. CsA increases mitochondrial superoxide production in endothelial cells.  
(A) DCFDA fluorescence in endothelial cells treated with vehicle, 0.25µM CsA, or 
H2O2, n=3-4 per group. (B, C) Mitosox fluorescence in endothelial cells treated with 
vehicle, (B) 0.25µM CsA, (C) 0.1µM NIM811, or 0.1µM FK506 for 24 hours, and 
then stained with 5µM Mitosox. Mitosox fluorescence was quantified by flow 
cytometry. Quantification of mean fluorescence intensity (MFI) is shown, n=4-5 per 
group. Error bars indicate SEM, and * P <0.05 for all experiments. 
 
 
Cyclosporin A treatment increases mitochondrial membrane potential  
While we and other groups have demonstrated that CsA increases ROS, the 
mechanism by which this occurs is not completely understood. It is known that CsA 
decreases MPTP opening in response to apoptotic stimuli, reducing the efflux of 
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mitochondrial contents, including ROS. It is less clear how CsA increase ROS in the 
absence of these stimuli. 
The MPTP is a nonselective calcium and ROS-responsive channel bridging the 
mitochondrial inner and outer membrane and is well known for its role in propagating 
cell death (Halestrap 2009). This opening is irreversible and spreads to neighboring 
MPTP complexes, causing depolarization waves across the mitochondrial membrane and 
collapsing the mitochondrial membrane potential. This irreversible MPTP activity is 
well-characterized in pathological settings, such as ischemia-reperfusion injury in 
cardiomyocytes and hypoglycemia-triggered neuronal cell death (Crompton 1999). More 
recently, the MPTP also has been shown to function under physiological conditions. In 
this state, the MPTP undergoes individual reversible openings that recover quickly 
without membrane depolarization or mitochondrial swelling (Halestrap 2009; Rasola et al. 
2010; Wang et al. 2012; Wang et al. 2008). This mode, termed “physiological flickering” 
or “superoxide flash,” is thought to have signaling or metabolic functions (Rasola et al. 
2010). One consequence of a superoxide flash is a brief dip in mitochondrial membrane 
potential, followed by recovery upon MPTP closure (Wang et al. 2012; Kowaltowski et 
al. 2000). Therefore, physiological flickering of the MPTP may act as a potential release-
valve for regulating the mitochondrial membrane potential.  
The mitochondrial membrane potential is closely linked to mitochondrial 
metabolism, and studies in isolated mitochondria have shown a direct correlation between 
the mitochondrial membrane potential and mitochondrial ROS production (Korshunov et 
al. 1997). Thus, we hypothesize that during non-apoptotic conditions, CsA increases ROS 
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by acting on the MPTP to decrease physiological flickering, resulting in increased 
mitochondrial membrane potential, leading to increased mitochondrial ROS production. 
To test this hypothesis, we utilized tetramethylrhodamine ethyl ester (TMRE), a 
cationic fluorescent dye that is readily sequestered by active mitochondria. Due to its 
cationic nature, the binding of TMRE to the mitochondria is membrane potential-
dependent (Wang et al. 2008). Endothelial cells treated with either CsA or NIM811 for 
48 hours showed substantially increased TMRE staining compared to vehicle treatment 
(Fig 3.3.). These data are consistent with the hypothesis that CsA increases mitochondrial 
ROS by increasing mitochondrial membrane potential.  
 
Fig. 3.3. CsA treatment increases mitochondrial membrane potential in 
endothelial cells. TMRE fluorescence in endothelial cells treated with vehicle, 
0.25µM CsA, 0.1µM NIM811 for 24 hours, and then stained with 100nM TMRE to 
detect mitochondrial membrane potential. TMRE fluorescence is detected by flow 
cytometry, quantification of mean fluorescence intensity is shown on the right with 
n=3-5 per group. Error bars indicate SEM, and * P <0.05. 
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Antioxidant treatment abolishes the pro-angiogenic effect of cyclosporin A on 
endothelial cells in vitro.  
While our data show that CsA increases mitochondrial ROS in endothelial cells, it 
is unclear whether the elevated ROS is responsible for the pro-angiogenic effects 
observed. ROS is known to be involved in angiogenesis as VEGFR activation result in 
NAPDH oxidase stimulation, which increases intracellular levels of the mitogenic H2O2, 
leading to endothelial cell proliferation and migration (Ushio-Fukai 2006).  
We hypothesize the CsA-induced ROS are responsible for the proliferative and 
migratory effect observed in CsA-treated endothelial cells. To test this hypothesis, we 
utilized both cellular and mitochondrial antioxidants to quench ROS. Co-treatment of 
endothelial cells on CsA therapy with the cellular antioxidant N-acetyl-cysteine (NAC) 
abolishes CsA-induced proliferation in vitro (Fig. 3.4.A). NAC treatment alone had no 
effect on either wild type or Dscr1 transgenic endothelial cells, which overexpress the 
endogenous calcineurin inhibitor DSCR1. Co-treatment with the mitochondrially 
permeant superoxide dismutase mimetic and peroxynitrate scavenger 
manganese(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP) also attenuates 
CsA-induced proliferation (Fig.3.4.B). Treatment with both NAC and MnTBAP 
decreased CsA-induced migration (Fig.3.4.C & D). Mitosox staining confirms that 
MnTBAP co-treatment with CsA reduces mitochondrial generated ROS (Fig.3.4.E). 
These results are consistent with the hypothesis that CsA promotes angiogenesis through 
a ROS-dependent mechanism.  
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Fig. 3.4. Antioxidant treatment abolishes cyclosporin A-induced endothelial cell 
activation, A-D. (A, B) Proliferation of primary endothelial cells after treatment 
with 0.25µM CsA plus (A) 5mM NAC, or (B) 10µM MnTBAP. Cell numbers were 
counted daily. * P <0.05 (between CsA and CsA + antioxidant groups). Results are 
representative of two experiments, with n=3 per group. (C, D) Representative images 
of endothelial cells migrating through a transwell filter in response to vehicle, 
0.25µM CsA, (C) 5mM NAC, or (D) 10µM MnTBAP. Black scale bars indicate 
100µm. Quantification of cell numbers per high-powered field (hpf) is shown below. 
Results are pooled from two experiments. (E) Quantification of Mitosox fluorescence 
in endothelial cells treated with vehicle or 0.25µM CsA for 24 hours with 10µM 
MnTBAP co-treatment.   
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Antioxidant treatment in melanoma tumor models decreases cyclosporin A-induced 
tumorigenesis 
Our experiments show that CsA treatment leads to increased endothelial cell 
proliferation and migration, which can be abolished with antioxidants. These results raise 
the possibility of in vivo therapy with antioxidants to treat CsA-associated cancers. NAC 
is an FDA approved drug commonly used as a mucolytic agent or to treat acetaminophen 
toxicity. In the body, NAC is converted to a precursor of the cellular antioxidant 
glutathione; external administration of NAC augments and boosts cellular antioxidant 
capabilities (Samuni et al. 2013). Clinically, NAC is well tolerated in single, intermittent, 
(Atkuri et al. 2007) or chronic use (Grandjean et al. 2000). 
We sought to determine whether antioxidant therapy has an effect on CsA- 
 
Fig. 3.5. Antioxidant treatment abolishes cyclosporin A-induced tumorigenesis in 
vivo. Tumor growth over time in mice treated with or without CsA and with or 
without 40mM NAC. WT C57/BL6 mice were supplied with NAC for 14 days, and 
then treated daily with 10mg/kg CsA for 14 days before inoculating subcutaneously 
with B16-F10 melanoma cells. Animals were maintained on CsA and or NAC 
treatment for the duration of the experiment. Tumor volume was measured on the 
indicated days. * P <0.05 (between CsA and CsA + NAC groups). Representative 
experiment shown from two experiments, n=5-9. Error bars indicate SEM, and * P 
<0.05 for all experiments.  
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associated tumorigenesis in vivo using the B16-F10 allograft melanoma model in WT 
mice. Oral NAC was delivered to mice in the drinking water at 40mM, a routinely used 
investigational dose (Aoi et al. 2014). NAC co-treatment in tumor-bearing mice on CsA 
therapy decreased tumor growth compared to CsA alone (Fig.3.5.). Tumor growth in 
mice on NAC and CsA co-treatment were indistinguishable from untreated mice. NAC 
treatment by itself also did not affect tumor growth. These data demonstrate the 
significance of CsA-induced ROS in an in vivo tumor model and the therapeutic potential 
for prophylactic prevention of CsA-induced tumorigenesis by administering antioxidants. 
 
 
Cyclosporin A increases ERK signaling in a ROS-dependent manner 
In endothelial cells, ROS can differentially affect numerous pathways depending 
on the particular ROS agent, its concentration and location (Maulik & Das 2002). Given 
the integration of ROS signaling in many essential endothelial cell processes, it is unclear 
which pathways CsA affects to promote ROS-dependent pro-angiogenic effects.   
To determine which pro-proliferative pathway CsA-induced ROS affects in 
primary endothelial cells, we assessed for activation in the mitogenic AKT and MAPK 
pathways and found that CsA treatment increased ERK but not AKT phosphorylation 
(Fig.3.6.A). Pre-treatment of endothelial cells with NAC prior to CsA treatment 
abolished CsA-induced ERK phosphorylation (Fig. 3.6.B), indicating this is a ROS-
dependent process. These data suggest that CsA-induced ROS promotes MAPK activity. 
ROS can change the oxidative-reductive state in a cell, affecting the enzymatic 
activity of proteins such as phosphatases, including those involved in mitogenic pathways 
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(Forman et al. 2004; Thannickal & Fanburg 2000). Low levels of ROS have been shown 
to deactivate phosphatases that negatively regulate mitogenic intermediaries, resulting in 
prolonged proliferative signaling (Meng et al. 2002). Consistent with this notion, we 
found that CsA treatment in endothelial cells prolonged ERK activation over time 
 
Fig. 3.6. Cyclosporin A-induced reactive oxygen species upregulates MAPK 
signaling. (A) Western blot of phospho and total ERK and AKT protein in endothelial 
cells after treatment with 0.25µM CsA or vehicle for 5min. (B, C) ERK 
phosphorylation in endothelial cells was examined by Western blot after treatment 
with (B) 5mM NAC for 30 min followed by 0.25µM CsA or vehicle for 5min, or (C) 
0.25µM CsA or vehicle for the indicated time. Phosphoproteins were normalized to 
their respective total protein levels with relative expression levels on the right for all 
experiments. (A-C) each lane is an individual experiment. Results are pooled from 4-5 
experiments. Error bars indicate SEM, and * P >0.05 for all experiments. 
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compared to vehicle treatment (Fig.3.6.C). Treatment with the supra-physiological  
5ng/mL EGF (physiological range: 10
-12
g/mL
 
(Joh et al. 1986)) was used as a positive 
control to demonstrate both ERK activation as well as its decline over time.  
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Discussion 
 
In Chapter 2, we showed that CsA promotes endothelial cell proliferation and 
migration in a calcineurin-independent manner. Here we argue that CsA achieves these 
effects through elevated mitochondrial ROS. In these experiments, we demonstrate that 
CsA and its non-immunosuppressive analog, NIM811, both act on the mitochondria to 
increase mitochondrial ROS and promote endothelial cell proliferation and migration. 
Neutralization of elevated ROS by either cellular or mitochondrial targeted antioxidants 
abrogates CsA-induced endothelial cell proliferation and migration. Prophylactic 
antioxidant treatment in tumor-bearing mice on CsA regimens significantly reduces the 
increased tumorigenesis seen with CsA treatment. In vitro studies in endothelial cells 
showed that CsA promotes ERK phosphorylation in a ROS dependent manner.   
A number of calcineurin-independent effects have been ascribed to CsA. CsA has 
been shown to increase p38 and JNK signaling in T cells (Matsuda et al. 2000) and 
inhibit mitochondrial calcium uptake in HeLa cells (Montero et al. 2004), effects not 
shared by other calcineurin inhibitors, either pharmacological or endogenous.  CsA has 
previously been shown to bind and inhibit P-glycoprotein (Morjani & Madoulet 2010). 
Brain and testis endothelial cells express high levels of P-glycoprotein in order to 
maintain the blood-brain or blood-testis barrier. Tumor cells can also express P-
glycoprotein as a means of drug resistance (Morjani & Madoulet 2010), however, this 
does not always extend to tumor endothelial cells (Tóth et al. 1996). Moreover, our 
experiments utilized lung endothelial cells, which do not express P-glycoprotein 
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(Demeule et al. 2001). Therefore, we do not expect the inhibition of P-glycoprotein by 
CsA to be a confounding factor in our results.  
While we show that antioxidant treatment of tumor-bearing mice in vivo 
decreases CsA-induced tumor growth, it is still unclear whether this is due to a decrease 
in tumor angiogenesis. This ambiguity could be addressed by staining for endothelial cell 
markers such as CD31 to reveal whether antioxidant treatment has any effect on CsA-
induced tumor angiogenesis.  
Oral ingestion of both CsA and NAC results in elevated drug levels in both tumor 
cells as well as the tumor microenvironment, all of which may also affect tumor 
angiogenesis. We have shown in vitro that CsA elicits pro-angiogenic responses directly 
in endothelial cells, but have not excluded the possibility that it may also act in a tumor 
cell-autonomous manner in vivo to induce angiogenesis as tumor-derived ROS can also 
promote neoplastic angiogenesis (Xia et al. 2007). Likewise, systemic administration of 
NAC could be affecting both the tumor tissue and also the tumor microenvironment. 
Since we postulate that CsA promotes ROS in a cyclophilin D-dependent manner in 
endothelial cells, the deletion of cyclophilin D in the host tissue should abrogate the 
effects of both CsA and antioxidant treatment on tumorigenesis. Utilizing a whole body 
cyclophilin D knockout transgenic mouse model would address whether CsA-induced 
effects are tumor cell autonomous or microenvironment based. Similarly, transgenic mice 
with conditional deletion of cyclophilin D specifically in endothelial cells could be used 
to determine whether CsA-induced tumorigenesis occurs only through its activity in 
endothelial cells.  
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CsA has not been described to have any cyclophilin-independent effects. Scant 
functional characterization of some cyclophilin proteins has been performed, but their 
specific functions are mostly unknown. Correspondingly, the effect of CsA binding to 
these proteins is unknown. An exception is cyclophilin D, where both its function and 
interaction to CsA has been thoroughly studied with biological relevance in multiple 
disease models (Giorgio et al. 2010; Elrod & Molkentin 2013). Since the effect of the 
CsA-cyclophilin D interaction on mitochondrial biology is well known, cyclophilin D is 
an attractive candidate as a calcineurin-independent mechanism responsible for the pro-
angiogenic effect of CsA in endothelial cells. However, NIM811 and CsA still bind to 
other intracellular cyclophilins. Therefore, the possibility of other CsA binding partners 
contributing to this effect cannot be ruled out and will be discussed in further detail in 
chapter 4.  
While we suspect that CsA acts through a ROS-dependent mitochondrial 
mechanism to increase endothelial cell proliferation and migration, we have not 
completely ruled out the contribution of ROS-independent mitochondrial effects. We did 
establish that CsA has no effect on cell death in the absence of apoptotic stimulus, as it 
known that CsA decreases apoptosis under cell death conditions (Norman et al. 2010). 
The effects of CsA-cyclophilin D interaction on other mitochondrial functions were not 
addressed in this study and future studies assessing mitochondrial metabolism, calcium 
signaling, fission/fusion, and mitophagy would be helpful in tackling this concern.  
Our data shows elevated Mitosox but not DCFDA staining in endothelial cells 
following CsA treatment. We hypothesize that CsA leads to an increase in the production 
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of mitochondrial ROS, which could enter the cytosol in the membrane-permeant form 
H2O2 to affect cellular redox signaling. Therefore, we expected to see elevated ROS 
levels in both compartments. As DCFDA staining shows no change with CsA treatment, 
it suggests cellular ROS levels are unchanged. However, the DCFDA marker may not be 
a representative readout of cytosolic ROS. Upon entering a cell, cleavage of DCFDA by 
cellular esterases converts it into a non-fluorescent ROS indicator, which becomes 
fluorescent when oxidized. This intracellular ROS probe is sensitive to oxidation by 
peroxyl, alkoyl, NO2, carbonate, and OH
∙
 radicals, but not to O2
-
  or H2O2 (in the absence 
of peroxidases) (Eruslanov & Kusmartsev 2010). H2O2 is a relatively stable ROS family 
member which can diffuse freely across membranes such as the mitochondrial membrane 
and has been implicated in physiological processes such as proliferation and growth 
arrest (Giorgio et al. 2007). The unreliability of the DCFDA probe to detect H2O2 causes 
it to be a less relevant indicator of the specific reactive oxygen species that may be 
responsible for the proliferative changes studied here. The addition of horseradish 
peroxidase or myeloperoxidase, which oxidizes DCFDA in the presence of H2O2, would 
allow us to determine the total cytosolic ROS in a cell. Alternatively, other hydrogen 
peroxide indicators such as Amplex Red (in combination with horseradish peroxidase) or 
Peroxy Green 1 and Peroxy Crimson 1 (Miller et al. 2007) could also be used.   
The mitochondrial membrane potential, which contributes to the proton-motive 
force to drive the regeneration of ATP from ADP, is generated and maintained by the 
oxidative-phosphorylative chain. Changes in the mitochondrial membrane potential can 
significantly affect mitochondrial bioenergetics, including the production of reactive 
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oxygen species from the ox-phos chain. Increasing the mitochondrial membrane potential 
through chemical means increases the production of hydrogen peroxide from the 
mitochondria (Korshunov et al. 1997). Our studies indicate that this is a mechanism by 
which CsA could potentially stimulate mitochondrial ROS production. This concept, as 
well as the background concerning relevant mitochondrial bioenergetics, are complex and 
will be discussed in depth in the summary chapter.  
While our data is consistent with the hypothesis that the increased mitochondrial 
potential is the cause of CsA-induced ROS, but we have not ruled out other potential 
means responsible for elevated ROS. A previous study in endothelial cells found that 
CsA treatment perpetuated ROS damage by inactivating the mitochondrial antioxidant 
manganese superoxide dismutase through an endothelial cell nitric oxide synthetase-
dependent mechanism (Redondo-Horcajo et al. 2010). Additionally, CsA has been shown 
to upregulate the expression of TXNIP, an inhibitor of the ROS scavenger thioredoxin, in 
renal mesangial cells (O’Connell et al. 2012). It is possible that all these sources could 
potentially contribute to CsA-associated ROS elevation, and future studies examining the 
effect CsA on each pathway in a single system would help evaluate the contribution of 
each of these ROS-producing pathways to CsA-associated ROS elevation.  
The major physiological source of ROS in endothelial cells is from the NADPH 
oxidase, where it is produced in response to pro-angiogenic stimulus (Maulik & Das 
2002). ROS serves as a signaling molecule which can induce VEGF receptor 
autophosphorylation, c-Src activation, and VE-cadherin phosphorylation (Ushio-Fukai & 
Nakamura 2008). Additionally, ROS by itself can induce VEGF expression (Xia et al. 
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2007). The studies presented here did not assess whether CsA-induced ROS has any 
effect on endogenous ROS-activated endothelial cell processes. Characterization of 
VEGF expression levels and downstream signaling using NIM811 (to bypass the effect of 
CsA on the VEGF-calcineurin-NFAT axis) and antioxidants would address this point. 
Our data showed that CsA treatment leads to prolonged activation of the MAPK 
effector ERK1/2 in vitro, which is highly suggestive that CsA may act to reduce its 
negative regulation, but does not show a causal relationship. Probing the activity of the 
mitogen-activated protein phosphatases (MKP1-10) with CsA and antioxidant treatment 
would help fill in the gap in knowledge. Furthermore, future experiments examining and 
manipulating the downstream ERK1/2 effectors are needed to show a direct effect of 
CsA-induced ERK activation and CsA-induced proliferative changes.  
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CHAPTER 4: SUMMARY AND DISCUSSION 
 
Summary of findings: overview 
In this thesis, we have identified a novel effect of the commonly used 
immunosuppressant cyclosporin A (CsA) in tumor angiogenesis. CsA is a potent inhibitor 
of the calcineurin pathway, which is involved in immune defense, memory consolidation, 
cardiovascular biology, and angiogenesis (Rusnak & Mertz 2000; Liu et al. 1991; Graef 
et al. 2001; Molkentin et al. 1998; Miyakawa et al. 2003). Our lab previously 
demonstrated that suppression of calcineurin in endothelial cells by its endogenous 
inhibitor Down Syndrome Candidate Region 1 (DSCR1) results in suppression of tumor 
angiogenesis and tumor growth (Baek et al. 2009). Paradoxically, chronic therapy with 
the calcineurin inhibitor CsA for transplant patients is associated with increased tumor 
incidence and progression. Here, we demonstrate for the first time that CsA treatment 
promotes tumor angiogenesis in vivo as well as endothelial cell proliferation and 
migration in vitro. We found that the pro-proliferative and migratory effects of CsA in 
endothelial cells occur in a calcineurin-independent manner, and is associated with 
increased mitochondrial reactive oxygen species (ROS). Additionally, treatment with 
antioxidants decreased CsA-induced proliferation and migration in vitro and CsA-
induced tumorigenesis in vivo. Our model is summarized in figure 4.1.  
Our studies have uncovered a previously unknown and targetable pathway 
through which CsA promotes tumorigenesis. However, our results raise many new 
questions, which will be discussed in the following pages along with future directions.  
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Fig. 4.1. Proposed model of CsA-induced tumor angiogenesis. CsA treatment in 
endothelial cells induces mitochondrial ROS in a calcineurin-independent manner, 
which promotes cell migration and proliferation. Increased endothelial cell 
proliferation and migration due to CsA treatment leads to increased tumor 
angiogenesis. Calcineurin (grey) inhibition still occurs, but the pro-proliferative 
effects of CsA is due to mitochondrial ROS. 
 
CsA, cancer, and angiogenesis 
 
Transplant-associated cancers: beyond skin cancers 
To accurately reflect on the cancer profile of patients on CsA therapy, we utilized 
skin cancer models to study the effects of CsA on tumorigenesis. Most studies of CsA-
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associated cancers also examine CsA in the context of skin tumorigenesis. There are a 
scattering of studies, however, that investigates the effects of CsA primarily on renal 
carcinoma or lymphocytes (Datta et al. 2009; Hojo et al. 1999; Mazière et al. 2005). A 
study by Guba et al in 2007 examined the risk of malignancy after kidney transplant in 
2419 transplant patients and found an elevated risk of skin cancers, but also a 17.6-fold 
increase in the relative risk of developing kidney cancer (Wimmer et al. 2007). This was 
similarly mirrored by another study in 35,000 kidney transplant patients, who had a 15-
fold increase in relative risk of kidney cancer (Kasiske et al. 2004). This elevation in 
kidney cancers in kidney transplant patients may be due to the kidney as the transplanted 
organ, as there is an organ-specific cancer risk arising from the transplanted organ 
(Engels et al. 2011).  
Non-hogkins lymphoma in transplant patients is termed posttransplant 
lymphoproliferative disorder (PTLD) (Engels et al. 2011), and is associated with 
reactivation of latent Epstein-Barr virus and T cell dysfunction, presumably due to 
immunosuppression. PTLD often resolves upon discontinuation or reduction of 
immunosuppressive therapy, but can be also treated with radiation or chemotherapy (Tsai 
et al. 2001; Gottschalk et al. 2005).  
Since kidney cancers are associated with an organ-specific etiology, and PTLD is 
strongly tied to immunosuppression, skin cancers appear to best represent a direct 
oncogenic effect of CsA treatment. Therefore, we conducted our study on CsA 
specifically in the context of skin cancers. Nonetheless, one should not marginalize the 
morbidity and mortality of non-skin solid tumors in organ transplanted patients. 
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Thorough investigation of the pathogenesis behind those tumors is important for 
decreasing the incidence and for the development of therapies.  
 
Cancer cell autonomous effects of CsA on tumorigenesis: CsA and ROS on tumor cells. 
 The direct effect of CsA on tumor cells have been examined by other groups and 
described earlier in Chapter 1 and summarized in Figure 2.0. CsA is known to promote 
TGF-β production and Ras signaling in transformed tumor cells, induce ATF3 expression, 
and suppress DNA repair proteins and UV induced apoptosis in keratinocytes (the tumor 
cells of origin).  
Our studies show CsA can act on the tumor microenvironment, specifically 
endothelial cells, through a ROS-dependent manner to increase cell proliferation and 
migration. Reactive oxygen species are often elevated in tumors and can affect a number 
of tumorigenic pathways in a cell-autonomous manner.  
ROS molecules are highly reactive can interact with DNA, leading to DNA 
damage. If left unrepaired or mis-repaired, this DNA damage results in mutations, paving 
the way for oncogenic transformation.  
ROS can also regulate various mitogenic signaling pathways through redox 
signaling. The MAPK pathway, which was demonstrated to be activated by CsA in 
endothelial cells, is overactive in many cancers. Elevated ROS in cancer cells has been 
shown to augment MAPK signaling, promoting tumor cell proliferation in a cell 
autonomous manner (Weinberg et al. 2010; Pelicano et al. 2004). ROS can also affect 
redox-sensitive transcription factors, for example, NF-κB and HIF-1α, which are 
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important in tumorigenesis (Bonello et al. 2007). Additionally, p53, a critical tumor 
suppressor, forms disulfide bonds when oxidized that interfere with its ability to bind to 
p53 response elements, negatively affecting its transcriptional activities (Sun et al. 2003). 
It is important to note that the relationship between ROS and tumorigenesis is 
complex, as it has also been found to negatively affect tumorigenesis. Radiation therapy 
exerts its tumoricidal effect by generating high levels of ROS. Elevated ROS has also 
been shown to lead to p38-dependent apoptosis in the setting of oncogene activation 
(Dolado et al. 2007). Therefore, while CsA-induced ROS in cancer cell could potentially 
lead to increased tumor growth, its actual contribution to tumorigenesis needs to be 
evaluated.  
 
Non-cancer cell autonomous effects of CsA on tumorigenesis: immune cells and 
fibroblasts 
 We show that CsA promotes tumorigenesis through its effect on endothelial cells. 
The tumor microenvironment is a diverse milieu with multiple cell types which can affect 
tumorigenesis. Therefore, it is important to consider that CsA may also affect these other 
cell types to indirectly influence tumorigenesis.  
Immune cells infiltrate tumors and secrete a number of inflammatory regulators. 
As CsA inhibits calcineurin-dependent T cell activation, it potently suppresses the 
adaptive immune response. It has been postulated that loss of immunosurveillance due to 
CsA treatment is a means by which transformed tumor cells can escape suppression by 
the immune system. Additionally, immunosuppression may also allow the unchecked 
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activity of oncogenic viruses. This is supported by greater HPV presence, which can 
cause skin cancers, in CsA-associated squamous cell carcinomas (Queille et al. 2007). 
However, no studies have shown a direct causal link between HPV and CsA-associated 
cancers, or whether they are two independent consequences of CsA therapy. 
Cancer immunity is a complicated and multifactorial interaction between immune 
cells, tumor cells, stromal and endothelial cells. Immune cells can both antagonize and 
promote tumor growth. Generally, prolonged presence of activated innate immune cells 
such as neutrophils and macrophages is seen as pro-cancerous. However, innate immune 
cells are also under regulation by the adaptive immune system, which has paradoxical 
effects on tumorigenesis that can vary depending on cancer type, cancer progression, cell 
type, and experimental conditions (de Visser et al. 2006). So while suppression of 
adaptive immune cells in the tumor microenvironment by CsA is likely to affect 
tumorigenesis, it is unknown what the effect is. Comparing the effects of CsA with other 
immunosuppressants such as rapamycin or corticosteroids on tumor growth in 
immunocompetent and immunodeficient mouse models would be helpful in delineating 
the immunosuppressive contribution of CsA to tumorigenesis.  
A large component of the tumor microenvironment is fibroblasts, often referred to 
as carcinoma-associated fibroblasts (CAF). These CAFs are poorly understood, including 
their cells of origin, but are believed to promote oncogenic signals to tumor cells. The 
effects of CsA on CAFs are not known. CsA has been shown to promote TGF-β 
production in tumor cells, which may activate fibroblasts to a CAF-like phenotype. 
However, unpublished data in our lab shows calcineurin activity may be important in 
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TGF-β stimulated fibroblast activation, and inhibition of calcineurin by CsA prevents 
fibroblast activation. It would be interesting to determine the cumulative effect of CsA on 
the stromal fibroblasts and the fibroblast mediated contribution of CsA to tumor growth. 
 
Functional effect of CsA on tumor angiogenesis 
Given the disorganized nature of tumor vasculature, the pattern of CD31 positive 
structures in CsA treated tumors is by no means reflective of more functional vessels, but 
suggests an increase in nutrient or oxygen delivery that could provide a benefit to solid 
tumors (Bergers & Benjamin 2003). Future experiments involving the injection of FITC-
lectin or FITC-dextrin, fluorescent markers of vessel permeability, into the circulation of 
tumor-bearing mice treated with CsA prior to harvesting would provide information on 
the fluid flow and permeability of these tumor vessels. Furthermore, in vivo assessment 
of tumor perfusion and oxygenation can be achieved through Doppler ultrasound or 
electrodes (Eppendorf electrodes or Recessed Microelectrodes) (Menon et al. 2003) 
Our studies show CsA treatment in vivo results in a higher number of short CD31 
positive structures in xenograft tumors, and in vitro CsA promotes endothelial cell 
proliferation and migration with no effect on matrigel tube formation. The data suggests 
that CsA promotes the earlier stages of angiogenesis, specifically proliferation and 
migration. Unlike physiological angiogenesis, the process of tumor angiogenesis places a 
greater emphasis on endothelial cell proliferation and vessel elongation compared to 
vessel remodeling and maturation (Nishida et al. 2006). Importantly, CsA treatment, 
through the upregulation of ROS, may further aggravate the imbalance of pro- to anti-
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angiogenic pathways, amplifying the dysfunctional but aggressive nature of tumor 
angiogenesis. Future studies providing more detailed characterization of CsA-associated 
vessels, such as the expression of angiogenic regulators VEGF, TSP-1, or activation of 
Notch, would contribute more fully to our understanding of the role of calcineurin in 
tumor angiogenesis.  
 
Effect of CsA on angiogenesis: contribution of tumor cells 
Tumor cells are able to exert changes in its microenvironment through either 
secreted factors or cell-to-cell contact. The major secreted promoter of angiogenesis is 
VEGF (Carmeliet 2005). CsA treatment in renal carcinoma cells has been shown to 
directly promote the transcription and expression of VEGF (Basu et al. 2009). The 
significance of VEGF in CsA-associated skin carcinoma in vivo would be an interesting 
area to explore with the anti-VEGF antibody bevacizumab. . It is not clear whether CsA-
induced VEGF production is due to calcineurin inhibition. Loss of calcineurin activity, 
through genetic deletion or pharmacological inhibition, in tumor cells could be used to 
evaluate the calcineurin-dependence of CsA-induced VEGF.   
CsA also induces the production of TGF-β in tumor cells (Hojo et al. 1999). 
While a potent enhancer of cancer metastasis, TGF-β also has been described to have 
both pro- and anti-angiogenic effects. High levels of TGF-β is known to inhibit 
angiogenesis but low levels of TGF-β signaling can promote endothelial cell proliferation 
and enhance VEGF induced angiogenesis (Walshe 2010). Additionally, in nutrient 
deprived contexts, TGF-β  promotes endothelial cell survival (Lu 2008), which can 
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provide an advantage in the harsh tumor microenvironment. Treating conditioned media 
from tumor cells with neutralizing TGF-β antibodies prior to application to endothelial 
cells in vitro would be helpful in determining the effects of tumor derived-TGF-β   on 
endothelial cells.  
Although it is known that CsA treatment induces TGF-β production, it is unclear 
whether it occurs through calcineurin-NFAT inhibition or through calcineurin-
independent cyclophilin binding. There are NFAT and AP-1 binding sites present in the 
TGF-β promoter (Nakano et al. 2007). Additionally, calcineurin-NFAT signaling has also 
been shown to regulate a switch in the response to TGF-β, from cell cycle inhibitory to 
proliferative (Singh et al. 2010). It is possible that CsA not only promotes TGF-β 
production in tumor cells, but also regulates the response to TGF-β signaling.   
While we found CsA increases ROS in endothelial cells, the phenomenon has also 
been reported in other cell types, such as smooth muscle cells (Krauskopf et al. 2005) and 
renal glomerular cells (O’Connell et al. 2012), suggesting it may be a common effect. 
Tumor-derived ROS may affect angiogenesis in two ways. First, tumor derived ROS may 
directly enter endothelial cells to promote angiogenic processes. . CsA treatment could 
elevate ROS levels in multiple cells types, including tumor cells, which can diffuse out 
into the surrounding environment, enter endothelial cells, and induce an angiogenic 
response. This notion could be tested by measurement of  intra-tumor and serum H2O2, a 
stable and membrane permanent ROS,. .  
Secondly, tumor-derived ROS has been shown to induce the transcription of  pro-
angiogenic factors such as VEGF (Xia et al. 2007). The angiogenic secretome in 
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conditioned media from tumor cells treated with CsA, antioxidant, or combination of 
both could be assessed using an antibody array to determine whether CsA affects 
angiogenic factors in a ROS-dependent manner.  
To determine the source of the ROS responsible for angiogenesis, overexpression 
of antioxidant genes such as superoxide dismutase or catalase specifically in tumor cells 
to quench tumor-derived ROS in a xenograft tumor model with CsA treatment would 
help separate the source of ROS responsible for angiogenesis; whether it is tumor or host 
derived.  
 
Effect of CsA on angiogenesis: contribution of smooth muscle cells  
In addition to the direct pro-proliferative and migratory effect of CsA on 
endothelial cells, CsA may also promote tumor angiogenesis through its effect on other 
cell types in the tumor microenvironment. In vascular smooth muscle cells, CsA has been 
demonstrated to block proliferation and modulate the vascular smooth muscle cell 
phenotype through a NFAT-independent mechanism (Garvey et al. 2010). The CsA 
binding partner cyclophilin A is secreted by smooth muscle cells and is linked to 
proliferation, vascular remodeling, and recruitment of inflammatory cells (Nigro et al. 
2011). Vascular smooth muscle cells modulate tumor angiogenesis through regulation of 
vessel diameter, permeability, and contractility, as well as by regulating endothelial cell 
sprouting (Raza et al. 2010). CsA present in the tumor microenvironment may act upon 
smooth muscle cells to contribute to the increased angiogenesis observed. Comparison of 
pericyte markers such as α–SMA, NG2, desmin between tumors from CsA or vehicle 
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treated mice, followed by in vitro characterization of vascular smooth muscle cells 
treated with CsA would contribute to a more complete understanding of the contribution 
of CsA-microenvironment effects towards tumor angiogenesis.  
 
Differential effects of CsA on the vascular system: established vessels vs. new growth 
Oral CsA treatment in transplant patients also results in other vascular side effects, 
the most notable being systemic hypertension. As discussed previously, CsA-induced 
hypertension is the consequence of several pathological changes including elevated 
endotehlin-1, decreased nitric oxide, and activation of the renal angiotensin system 
(Olyaei et al. 2001). Of note, the primary effect of CsA in the established adult 
vasculature is an increase in vascular tone; excessive vessel sprouting or angiogenesis has 
not been described. Physiologic adult vasculature is composed of mature and quiescent 
endothelial cells, which are long-living with low proliferative potential (Bergers & 
Benjamin 2003).  
There appears to be a context-dependent response of endothelial cells to CsA 
treatment.  Our studies on proliferating endothelial cells and tumors demonstrate CsA 
treatment further increases endothelial cell proliferation and angiogenesis, whereas in the 
established quiescent vasculature, CsA treatment elevates vasculature tone leading to 
hypertension.  These different outcomes are dictated by unclear mechanisms, but may 
allude to the differential responses between quiescent or activated endothelial cells to 
ROS (Yung et al. 2006). In established mature vessels, redox signaling can cause 
endothelial dysfunction, promote secretion of inflammatory cytokines, hinder 
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vasorelaxation, or induce apoptosis (Yung et al. 2006). Furthermore, elevated ROS 
oppose vasodilation by converting the vasodilatory nitric oxide into the inactive 
peroxynitrite, diminishing the vasoactive capacity in the vascular wall (Yung et al. 2006). 
In the context of pathologic angiogenesis, the pro-angiogenic regulator VEGF-A has been 
shown to steer the direction of ROS signaling towards cell division and migration (Yung 
et al. 2006; Ushio-Fukai 2006; Xia et al. 2007). Therefore, the tumor microenvironment 
may provide a pro-angiogenic environment for CsA signaling whereas the same CsA 
treatment in established vasculature results in hypertensive responses.  
 
 
Calcineurin-independent effects of CsA 
 
Untangling the pathways: small molecule inhibition of calcineurin and cyclophilins 
Calcineurin Inhibitors: FK506 vs CsA  
While the best studied target of CsA is calcineurin, CsA also interacts with other 
molecules. Therefore, to determine whether calcineurin inhibition is responsible for CsA-
induced proliferation and migration in endothelial cells, we compared the effects of 
several other calcineurin inhibitors to CsA. Previous studies have shown that 
overexpression of the endogenous inhibitor Down Syndrome Candidate Region-1 
(DSCR1) suppresses VEGF induced angiogenesis by inhibiting the calcineurin pathway 
(Baek et al. 2009; Hesser et al. 2004; Chan et al. 2005; Yao & Duh 2004; Iizuka et al. 
2004). We showed that treatment with CsA in endothelial cells overexpressing DSCR1 
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increased proliferation, suggesting CsA acts in a dissimilar manner to DSCR1. We also 
compared the effects of CsA with the independent pharmacological calcineurin inhibitor, 
FK506. Also known as tacrolimus, FK506 is a small molecule which binds to the 
intracellular proteins FK Binding Proteins (FKBPs) to form a calcineurin-inhibitory 
complex (Rusnak & Mertz 2000) that is distinct from the CsA-cyclophilin complex. The 
only similarity between CsA and FK506 is the ability to inhibit calcineurin. Therefore, 
FK506 should theoretically act as an excellent control to determine the calcineurin-
dependence of the endothelial cell effects seen with CsA treatment. 
We determined the calcineurin-dependence of the effects of CsA on endothelial 
cells by comparing it to FK506. Treatment with the clinically relevant dose 
0.15mg/kg/day of FK506 in vivo did not increase B16-F10 tumor growth compared to 
control treatment, while treatment with CsA promoted tumor growth. FK506 treatment 
decreased VEGF-induced migration, in direct contrast to CsA, which increased 
endothelial cell migration. CsA, but not FK506, treatment increased endothelial cell 
proliferation. Interestingly, treatment with FK506 inhibited endothelial cell growth, but to 
a lesser magnitude than calcineurin inhibition via DSCR1 (Baek et al. 2009).   
These data are consistent with our hypothesis that CsA promotes an endothelial 
cell phenotype in a calcineurin independent-manner. As a calcineurin inhibitor, FK506 is 
expected to vastly decrease endothelial cell proliferation compared to vehicle treated, but 
the magnitude of its effect in these experiments, while significant, is paltry. This effect 
may reflect an off-target effect of FK506 on FKBPs, which fall under the immunophilin 
family of proteins (Barik 2006). FK506 binds to multiple FKBP family members, which 
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has cellular roles that include calcium regulation(MacMillan 2013), and inhibition of 
TGF-β signaling (Spiekerkoetter et al. 2013). The FKBPs are highly expressed in 
endothelial cells (Higgins et al. 2003) and loss or inhibition of FKBPs in the vascular 
compartment results in decreased nitric oxide production and increased TGF-β and BMP 
signaling (Spiekerkoetter et al. 2013). The outcomes of TGF-β signaling in endothelial 
cells can be variable depending on context, but have been shown to promote angiogenesis, 
wound healing responses, and tube formation. Treatment with FK506, through 
sequestering FKBPs, a negative regulator of TGF-β, could potentially enhance TGF-β 
signaling in endothelial cells, opposing calcineurin inhibition, resulting in only a slight 
depression in endothelial cell proliferation, as seen in our studies.  
FK506 may also have a direct negative effect on tumor progression independent 
of endothelial cells as a previous study found topical applications of FK506 inhibited 
chemically-induced skin tumorigenesis and was associated with decreased IL-1α levels 
(Yamamoto & Jiang 1994). These studies, along with our data, indicate that while FK506 
and CsA are often considered comparable drugs clinically and experimentally, they are 
indeed very different molecules which can have a myriad of unrelated calcineurin-
independent effects. We show they have different effects on tumorigenesis, but this may 
extend to other physiological effects as well. Therefore, the clinical side effect profiles of 
these two drugs should be evaluated independently and their use in experimental studies 
should take into consideration the dissimilar off-target effects.  
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Cyclophilin inhibitors: NIM811 vs CsA 
Due to the calcineurin-independent effects of FK506 and the possible 
confounding factor of FKBP signaling, FK506 may not be an ideal control for 
determining the calcineurin-dependency of the effects seen with CsA. Therefore, we then 
used NIM811, a non-immunosuppressive cyclosporin analog. NIM811, along with 
Alisporivir (DEB025), was originally developed as a potential therapy for hepatitis C, 
which binds to cyclophilins as part of its viral life cycle (Hopkins & Gallay 2012). 
NIM811 is identical in chemical structure to CsA with the exception of an extra methyl 
group on amino acid 4 (Rosenwirth et al. 1994), rendering it unable to bind to calcineurin 
and an ideal control to test the calcineurin-dependence of the effect of CsA on endothelial 
cells. The binding of NIM811 to cyclophilin proteins are unchanged compared to CsA 
and unaffected by this side group difference (Rosenwirth et al. 1994). When treated with 
NIM811, endothelial cell proliferation increased in a manner comparable to when treated 
with CsA. Both NIM811 and CsA treatment induced a similar bell-shaped growth curve, 
showing both cyclosporin analogs exert the same dose-dependent effect on proliferation. 
Additionally, NIM811 also promotes endothelial cell migration across a transwell filter. 
These data are in accordance with the hypothesis that CsA promotes endothelial cell 
proliferation and migration in a calcineurin-independent manner.  
 
Cyclophilin inhibitors: clinical implications 
 These results clearly identify calcineurin-independent effects of CsA on 
endothelial cells, but also raise questions regarding the clinical usage of CsA analogs. 
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Non-immunosuppressive cyclosporin analogs are currently in development for treatment 
of hepatitis C (hep C). Inhibition of cyclophilins with cyclosporins inhibits viral 
replication. Three cyclosporin derived non-immunosuppressive cyclophilin inhibitors: 
Alisporivir (Debio-025), SCY-635, and NIM811, are currently in investigation as 
potential therapy for hep C (Hopkins & Gallay 2012). Our studies showing that the 
cyclosporin analog NIM811 promotes endothelial cell proliferation highlights a potential 
oncogenic risk with cyclophilin inhibitors similar to the effect seen with CsA. The 
completed clinical trials of these cyclophilin inhibitors have not found an increase in 
cancer risk or aberrant angiogenic events (Gunter et al. 2010). However, this may reflect 
the duration of drug use in these trials, usually lasting 4 weeks or less. A Phase IIa trial 
with Alisporivir lasting 48 weeks also did not identify increases in cancer risk or vascular 
events (Alberti et al. 2012; JM et al. 2012). While its similarities to CsA label this 
cyclophilin inhibitor as a potentially pro-tumorigenic drug, to the best of our knowledge, 
we are the only group to study the effect of NIM811 on endothelial cells. So far no 
clinical data has emerged which would cement an association between NIM811, or other 
cyclophilin inhibitors, and increased cancer risk. As these cyclophilin inhibitors are still 
investigational therapies, they have not yet been thoroughly tested in patient populations. 
Additionally, transplanted associated cancers generally appear after years of continuous 
treatment, a scenario which cyclophilin inhibitors have not yet been subjected to. The 
cancer risk found with CsA treatment in transplant patients is dose dependent. Therefore, 
given the nature of hep C treatment, which is shorter in duration than transplant 
immunosuppression, the cumulative dose of cyclophilin inhibitor accrued over the 
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duration of treatment may not be sufficient to affect cancer risk. Taken together, these 
cyclophilin inhibitors, in their current clinical niche, do not appear to pose a significant 
cancer risk. Nonetheless, our studies comparing CsA and NIM811 suggests additional 
investigations into the safety of the cyclophilin inhibitors maybe warranted, especially in 
regards to potential cancer risk.  
An interesting finding from our studies was that both CsA and NIM811 treatment 
induced a bell-shaped dose-dependent effect on endothelial cell growth in vitro. 
Compared to vehicle treated controls, CsA and NIM811 caused an increase in endothelial 
cell growth starting at 10nM and increased with  drug concentration until a maximum of 
250nM, then causes cytotoxicity at >1M. This data demonstrates the complexity of the 
cellular response to these drugs, and possibly reflects the combined effect of more than 
one affected pathway. At least two distinct and opposing effects on proliferation have 
been ascribed to CsA in endothelial cells through two different pathways. We show CsA, 
at low levels, promotes endothelial cell proliferation through a calcineurin-independent 
and ROS dependent pathway. At high levels CsA  inhibits endothelial cell migration, 
tube formation, and corneal angiogenesis through calcineurin inhibition (Hernández et al. 
2001). Additionally, ROS signaling can be either pro-mitogenic or pro-apoptotic 
depending on its levels (Yung et al. 2006). The delicate balance in which CsA induces 
multiple and sometimes opposing effects due to drug concentrations and cellular context 
may explain the difficulty of managing its therapeutic window. While CsA has 
revolutionized the transplant field by preventing graft rejection, its use is riddled with 
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multiple severe side effects. Taking into consideration the literature as well as our studies, 
clinical indications for CsA should instead consider other, more specific and safer drugs. 
 
Calcineurin loss and cell migration 
To determine whether CsA promotes angiogenesis in a calcineurin-dependent or 
independent manner, we used the lox-stop-lox technology to create cells in which the 
calcineurin B subunit can be genetically deleted, leading to the degradation of calcineurin 
A and loss of calcineurin activity. Loss of calcineurin nearly completely abolished 
endothelial cell migration across a transwell filter when compared to calcineurin-
competent cells. While unexpected, this is not surprising given that calcineurin-NFAT 
signaling promotes tumor cell migration and tumor invasion through integrin signaling 
(Liu et al. 2010; Jauliac et al. 2002). Additionally, inhibition of calcineurin through 
overexpression of DSCR1 (Iizuka et al. 2004) or treatment with FK506 decreased 
migration in vitro. In endothelial cells, NFAT promotes endothelial cell migration 
through upregulation of Cox-2 (Hernández et al. 2001). These studies indicate that 
calcineurin activity is important for endothelial cell migration, a critical aspect of 
angiogenesis. Therefore, the net migratory effect of CsA seen here is the sum of a large 
pro-migratory effect of CsA-induced ROS negating the anti-migratory effect of 
calcineurin inhibition. This further supports the hypothesis that CsA is affecting 
endothelial cell biology in a calcineurin-independent manner. Based on our results and 
these studies, current experiments in our laboratory now focus on the involvement of 
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calcineurin in fibroblast activation, in which cell migration and adhesion plays an integral 
role.  
 
Calcineurin-independent effects of CsA: why Cyclophilin D and the mitochondria? 
Despite the importance of calcineurin signaling in endothelial cell biology and 
angiogenesis, we have demonstrated the calcineurin inhibitor CsA is able to promote 
angiogenesis in a calcineurin-independent manner. Binding of CsA to cyclophilin A 
forms a calcineurin-inhibitory complex. In addition to cyclophilin A, CsA also binds to 
other cyclophilin family members, resulting in calcineurin-independent effects. 
Cyclophilins are a family of proteins with peptidyl-propyl isomerase functions, able to 
catalyze the cis-to-trans reaction. Binding of CsA to cyclophilins disrupt their catalytic 
function (Nigro et al. 2013). While conserved from yeast to humans, very little is known 
about the physiological role of the cyclophilin proteins. Knockout of all cyclophilins in S. 
cervasie did not yield any phenotypes (Dolinski et al. 1997), suggesting they may be 
important only during pathological or stressed circumstances. In mammals, cyclophilins 
have been linked to a number of pathological conditions. Cyclophilin A, in particular, has 
been associated with atherosclerosis, cancers, and inflammatory diseases (Nigro et al. 
2013). As CsA-induced angiogenesis occurs in a calcineurin-independent manner, , we 
theorize that it results from CsA binding to cyclophilin proteins. The most pronounced 
and consistent phenotype of pan-cyclophilin inhibition is mediated by cyclophilin D 
inhibition. Loss of cyclophilin D activity through pharmacological inhibitors or genetic 
deletion results in a ‘stiff’ pore that is resistant to opening in response to stimulus, such as 
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cell death signals. Despite being a pan-cyclophilin inhibitor, the use of CsA in multiple 
cell types is remarkably specific in its ability to decrease cell death in response to 
apoptotic stimulus, underlying the importance of cyclophilin D to cellular homeostasis.  
 
Other cyclophilins: possible contributions to angiogenesis 
While cyclophilin D remains the most obvious modulator of CsA pro-proliferative 
and migratory effects in endothelial cells, we did not rule out the contribution of other 
cyclophilins, or cyclophilin-independent effects of CsA. To this date, no cyclophilin-
independent effects of CsA have been described, but the absence of its knowledge does 
not necessary rule out its existence. Additionally, while inhibition of cyclophilin D is the 
most pronounced cellular effect of pan-cyclophilin inhibitors, CsA still binds to other 
cyclophilin family members, the effects of which are unknown.  
 
Cyclophilin A 
Cyclophilin A, which binds CsA to form the calcineurin inhibitory complex, is the 
most abundant cyclophilin family member, constituting about 0.1-0.6% of total cellular 
protein and is characterized with diverse contextual and cell-specific functions. It has 
been implicated in pathological conditions such as abdominal aortic aneurysm, 
atherosclerosis, diabetes, cancer, neurodegeneration, and several inflammatory conditions 
(Nigro et al. 2013). In response to inflammatory stimulus, Ang II, or other stressors, 
cyclophilin A can be secreted from macrophages and vascular smooth muscle cells as an 
inflammatory cytokine, and can act on vascular smooth muscle cells to increase matrix 
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metalloprotease production, promote growth and decrease apoptosis, which contributes to 
vascular remodeling (Nigro et al. 2011). Cyclophilin A signaling in endothelial cells has 
also been shown to increase adhesion molecules, decrease eNOS, and promote apoptosis 
(Nigro et al. 2013). Exogenously administered cyclophilin A has a biphasic effect on 
endothelial cell activation where low levels promoted angiogenesis but high levels 
decreased endothelial cell viability (Kim et al. 2004). 
These studies indicate an important but complex role of cyclophilin A in 
pathological vascular conditions. It is unclear whether  cyclophilin A has a role in tumor 
angiogenesis, despite being strongly linked to cancer progression and metastasis in a cell-
autonomous manner (Lee & Kim 2010).  
Previous studies have shown knockdown of cyclophilin A protects against TNF-α 
induced endothelial cell apoptosis (Nigro et al. 2011). While we did show increased cell 
numbers with CsA treatment, it was due to increased proliferation without any change in 
apoptosis. As a cyclophilin inhibitor, CsA sequesters and inhibits cyclophilin A activity 
in endothelial cells, a phenotype which should resemble cyclophilin A deletion mutants. 
However, the phenotypes we observed in endothelial cells after treatment with CsA, and 
to a lesser extent, NIM811, do not appear to phenocopy cyclophilin A loss described 
elsewhere. Therefore, cyclophilin A inhibition by CsA is unlikely to be responsible for 
the pro-angiogenic effects of CsA. 
 
Cyclophilin B 
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Cyclophilin B is another cyclophilin that is both secreted and retained in the 
endoplasmic reticulum, and is important for migration and adhesion of immune cells and 
protein folding (Mckeon 1994; Allain et al. 2002). Cyclophilin B expression and activity 
has also been found to be aberrant in several tumor types in a cell autonomous manner. 
For example, cyclophilin B is overexpressed in 80% of hepatocellular carcinomas and 
colon cancers, where it is transcriptionally regulated by HIF-1α and protects against 
cisplatin and hypoxia-induced apoptosis. In the same study, cyclophilin B was also 
shown to regulate HIF-1α associated angiogenesis by inducing VEGF production (Kim et 
al. 2011). Furthermore, cyclophilin B was also found to support glioblastoma multiform 
tumor cell survival by stabilizing the oncogenic proteins myc and p53, likely through its 
chaperone activity (Choi et al. 2014). In harsh oxidative conditions, cyclophilin B may 
also indirectly protect against oxidative damage by stabilizing myc, leading to increased 
transcription of UCP2, a mitochondrial uncoupling protein (Choi et al. 2014). These 
studies indicate a broad potential role of cyclophilin B in a cancer cell-autonomous 
manner. In the vasculature, however, cyclophilin B is not known to be expressed or have 
a physiological role. While cyclophilin B has been shown to be expressed in endothelial 
cells after shock wave stress (Holfeld et al. 2014), it has not been otherwise described to 
be present or functional in endothelial cells or angiogenesis.  
Inhibition of cyclophilin B by CsA in tumor cells could potentially decrease 
hypoxia-induced HIF-1α responses such as angiogenesis and also destabilize mutant p53 
and oncogenic c-myc, which could lead to decreased protection against oxidative stress. 
This may explain the increased ROS-dependent tumor angiogenesis in vivo seen in the 
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setting of CsA treatment. However, it does not account for the effects of CsA on 
endothelial cells in vitro, which are untransformed primary cells cultured in normoxic 
conditions.   
 
Cyclophilins C & E 
 Also discovered as a binding partner to cyclosporin A, cyclophilin C is expressed 
at much lower levels than cyclophilin A and has lower binding affinity to CsA than either 
cyclophilin A or B (Schneider et al. 1994). Little is known about the physiological 
function of cyclophilin C. Similarly, cyclophilin E, a nuclear and RNA binding 
cyclophilin, was recently described to bind to influenza viral proteins to retard their life 
cycle but is otherwise poorly understood (Wang et al. 2011). These proteins have not 
been described to be important in tumorigenesis, and none have been described to 
participate in angiogenesis. The outcomes of inhibition of these cyclophilins by CsA are 
unclear. 
 
Unbiased screen vs. candidate approach for CsA interactors 
While other cyclophilin family members, in particular, cyclophilin A, may be 
involved in pathological endothelial cell biology, cyclophilin D still remains the most 
attractive candidate to explain the proliferative and migratory phenotype seen with CsA 
treatment. Nevertheless, future studies are needed to definitively rule out the contribution 
of other CsA interactors, either cyclophilins or other molecules, to the pro-proliferative 
phenotype observed with CsA.  
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In this study, I have taken a candidate approach where I identified a likely target 
protein through a literature analysis. Subsequent testing of the phenotypical output such 
as the mitochondrial ROS was consistent with my hypothesis. To fully confirm this 
hypothesis, genetic manipulation should be used.  
Transgenic mice lacking cyclophilin D are viable and fertile and are protected 
from ischemia-reperfusion injury in vivo (Nakagawa et al. 2005) but display increased 
anxiety and brain white adipose tissue (Luvisetto et al. 2008), indicating a role for 
cyclophilin D in mitochondria-associated cell death and metabolism. Primary endothelial 
cells isolated from mice lacking cyclophilin D is expected to behave similarly to wild-
type endothelial cells treated with CsA or NIM811, which inhibits cyclophilin D. In fact, 
mitochondria isolated from cyclophilin D null cells have MPTP that are resistant to 
calcium-induced opening, in a manner similar to inhibition of cyclophilin D by CsA 
(Nakagawa et al. 2005). Given my hypothesis, I expect endothelial cells isolated from 
cyclophilin D null mice to have increased proliferation and migration in vitro compared 
to wild-type endothelial cells, similar to CsA treatment. Additionally, cyclophilin D null 
endothelial cells are expected to display increased mitochondrial membrane potential and 
mitochondrial ROS production compared to wild-type endothelial cells. Xenografted 
tumors on cyclophilin D null mice are expected to have increased tumor growth and 
angiogenesis. To test whether endothelial cell cyclophilin D is important for CsA-induced 
tumor angiogenesis in vivo, one can conditionally delete cyclophilin D specifically in 
endothelial cells, rather than complete elimination of cyclophilin in all host cells. 
Breeding the transgenic VE-cadherin Cre recombinase mouse with the transgenic 
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cyclophilin D
loxP/loxP
 mouse (Schinzel et al. 2005) should yield transgenic mice with 
deletion of cyclophilin D only in endothelial cells. If endothelial cells are responsible for 
tumor angiogenesis and growth in CsA-treated animals, then loss of cyclophilin D 
specifically in the endothelial cells should mimic CsA treatment in wild-type animals 
when subjected to a tumor model. Any deviations from these expected outcomes, either 
partially or completely, would indicate that CsA is either not binding to cyclophilin D or 
is affecting multiple pathways in addition to cyclophilin D to result in pro-angiogenic 
effects.  
If cyclophilin D loss does not phenotypically mimic CsA treatment in vitro and in 
vivo on endothelial cells and tumor growth, it is possible that CsA is exerting an effect 
through another cyclophilin protein, or a yet unidentified non-cyclophilin pathway. If we 
assume CsA is exerting its effects through another cyclophilin protein, then systematic 
siRNA knockdown of all 7 mammalian cyclophilin genes (16 unique proteins) should 
identify the CsA interactor(s) responsible for increased proliferation, migration, and 
mitochondrial ROS in endothelial cells.  
To more broadly understand the effects of CsA and identify potential interacting 
proteins responsible for the effects observed, including non-cyclophilin proteins, it would 
be pertinent to use an unbiased screen. Unlike a targeted candidate approach, an unbiased 
screen systematically manipulates a much larger number of potential targets. Using a 
broader approach, such as an unbiased library of RNA interference (RNAi), to 
knockdown single genes in endothelial cells with or without CsA treatment, would allow 
for identification of genes that are immediately downstream of CsA-induced readout such 
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as cell proliferation and ROS generation. In this case, RNAi knockdown of the putative 
CsA interactor would then negate the pro-proliferative and pro-ROS effects of CsA 
whereas RNAi knockdown of unrelated transcripts should not affect CsA’s effects on 
proliferation and ROS (when compared to vehicle-treated). Potential targets would then 
be identified and direct binding to CsA would be confirmed through immunoprecipitation. 
Further characterization studies using FK506 and NIM811 would be expected to agree 
with existing experiments. The RNAi approach has been used extensively but is not 
without flaws as RNA interference only partially suppresses target gene expression and 
may have off-target effects on unrelated transcripts. 
 A more recent screen uses the newly developed clustered regularly interspaced 
short palindromic repeat (CRISPR)-Cas system, which was conceived from a RNA-based 
prokaryotic immune system (Wang et al. 2014). In this system, lentiviral vectors carry 
small segments of RNA, corresponding to the gene of interest, engineered as single-guide 
RNA (sgRNA), and direct Cas nucleases (usually Cas9, also expressed from the same 
viral vector) to cause double-stranded cleavage of matching targeted genomic DNA 
sequence (Shalem et al. 2014; Zhou et al. 2014; Wang et al. 2014). This allows for 
specific genomic deletion of a target gene. When used in combination with a library, 
either an unbiased or focused library, it is possible to individually delete target genes and 
then perform functional studies after subjecting to experimental treatments. Using this 
technology, one can identify proteins that either interact with CsA or are downstream of 
CsA interactors by screening for loss of CsA-induced cell proliferation and elevated ROS 
in cells. The advantage of the CRISPR-Cas9 screening system over the RNAi screening 
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system is that suppression of the target gene is complete due to its excision, whereas the 
RNAi system only partially suppress the target gene. A limitation of both systems is that 
in addition to identifying direct CsA interactors, they would also identify genes 
downstream of those proteins. Therefore, once target genes are identified, direct CsA 
interaction would need to be confirmed with immunoprecipitation studies.  
Genetic screens, either the RNAi or CRISPR-Cas9 system, would provide an 
unbiased means to identify CsA interactor(s) or confirm the current selected candidate 
that is/are responsible for the pro-angiogenic effects seen. Future studies using either one 
of these systems would greatly strength my hypothesis and may provide additional targets 
to understanding the tumorigenic effects of CsA.   
 
 
Relationship between ROS and CsA 
 
Mitochondria and ROS: evidence for the actions of CsA 
Treatment with CsA or its non-immunosuppressive analog NIM811 results in 
increased mitochondrial ROS and cell proliferation, which was abolished with 
antioxidant co-treatment. Moderate increases in ROS have been shown to promote 
mitogenic signaling pathways (Thannickal & Fanburg 2000), consistent with our data. 
 CsA is also known to inhibit calcium-induced irreversible MPTP opening in the 
setting of mitophagy or cell death. Inhibition of cyclophilin D during cell death raises the 
stimulus threshold required for the collapse of the mitochondrial membrane potential, 
ultimately decreasing apoptosis (Halestrap 2009; Kim et al. 2003). This property of CsA 
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is currently exploited to manipulate ischemia-reperfusion injury in cardiomyocytes 
(Halestrap & Richardson 2014).     
In the absence of cell death signals, treatment with CsA increases mitochondrial 
ROS production, in agreement with previous studies (Krauskopf et al. 2005; Redondo-
Horcajo et al. 2010; Akool et al. 2012). This process originates from an alternative 
mitochondrial pore state termed ‘physiological flickering’. In this reversible state, the 
transient opening of the MPTP is brief, isolated, stochastic, reversible, and does not result 
in membrane depolarization or cell death (Wang et al. 2012). Instead, individual 
reversible MPTP opening events are thought to act as a pressure release valve to regulate 
membrane potential, ultimately affecting mitochondria metabolism and the mitochondria-
cytoplasm crosstalk (Wang et al. 2012). Changes in mitochondrial membrane potential 
can alter the production of ROS (Korshunov et al. 1997), a byproduct of the electron 
transport chain during the process of oxidative phosphorylation. We hypothesize that 
inhibition of the reversible MPTP opening by CsA increases mitochondrial membrane 
potential, leading to increased ROS production. In order to fully appreciate the effects of 
CsA on mitochondrial biology, a thorough summary of mitochondrial bioenergetics 
leading to ROS production will be presented in the following section, followed by a 
discussion on the effects with CsA on this system. 
   
Oxidative-phosphylorative pathway 
The mitochondrion is a major source of reactive oxygen species, produced as a 
byproduct of the electron transport chain. The electron transport chain is the final portion 
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of cellular respiration in which high energy electrons from energy-rich substrates such as 
NADH and FADH2 are transferred, in a sequential and stepwise manner, to various 
energy carriers along the chain, until it becomes accepted by oxygen to form water. The 
fall of electrons down its energy gradient results in the generation of an electrochemical 
gradient across the mitochondria inner membrane which serves as the driving force for 
the regeneration of ATP. Comprehension of mitochondrial bioenergetics, especially 
oxidative phosphorylation, is critical to understanding how regulating MPTP activity can 
affect mitochondrial reactive oxygen species production.  
The mitochondrion is separated into two compartments (the intermembrane space 
and the matrix) by two membranes (outer and inner mitochondrial membrane) through 
which electrochemical gradients can be generated and exploited for energy production. 
The outer mitochondrial membrane defines the mitochondria as an organelle. In between 
the outer mitochondrial membrane and the inner mitochondrial membrane is the 
intermembrane space, which has a similar electrolyte and small solute composition as the 
cytosol. The inner mitochondrial membrane is highly convoluted and folded, thereby 
presenting a large surface area through which metabolic reactions can take place. The 
inner mitochondrial membrane encloses the mitochondria matrix, which is highly basic 
and negatively-charged (Rich & Marechal 2010).  
In eukaryotes, the electron transport chain is composed of five major complexes 
and two electron carriers. High energy substrates such as NADH (or FADH2) are 
generated in the mitochondrial matrix by the citric acid cycle. NADH in the matrix is 
taken up by complex I (also known as the NADH dehydrogenase), a large flavoprotein 
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complex which contains iron sulfur redox centers and spans the inner mitochondrial 
membrane. Complex I then acts to remove two electrons from NADH and deposits them 
onto Coenzyme Q (CoQ), reducing the oxidized CoQ (ubiquinone) to reduced CoQ 
(ubiquinol). This electron transfer from NADH to CoQ also drives the movement of 4 
protons (H
+
) from the mitochondrial matrix out into the intermembrane space, 
contributing to the electrochemical gradient. CoQ is a lipid-soluble mobile electron 
carrier that can then move from the membrane-spanning complex I to complex III (Rich 
& Marechal 2010).  
Complex II (also known as succinate dehydrogenase) also supplies reduced CoQ 
to Complex III, but does so by converting succinate to fumarate, using FADH2 as the 
high energy intermediate. Unlike complex I, III, IV, or V, complex II does not pump H
+
 
(Rich & Marechal 2010).  
Reduced CoQ generated from Complex I (or II) is taken up by Complex III (also 
known as cytochrome c reductase) it is bound to cytochrome b and the electrons are 
transferred onto cytochrome c at the Rieske 2Fe/2S center. One electron from the reduced 
CoQ is placed onto cytochrome c during each cycle while the other electron is passed 
from cyt.bL onto cyt.bH to regenerate the oxidized CoQ in a process called the Q cycle. 
While the Q cycle does not affect the final output of complex III, where two electrons are 
transferred from one CoQ onto two cytochrome c (each cytochrome c can only carry one 
electron), the Q cycle is a potential source of ROS production and will be addressed later. 
For each CoQ that is oxidized, two H
+
 are pumped from the mitochondrial matrix into the 
intermembrane space (Rich & Marechal 2010).  
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Cytochrome c is a mobile electron carrier in the intermembrane space. Each 
reduced cytochrome c carries one electron from Complex III to Complex IV (also known 
as cytochrome c oxidase) where it is passed through a sequence of heme and metal 
groups, generating energy to pump 2 H
+
 into the intermembrane space. The terminal 
electron acceptor in Complex IV is O2, which requires four electrons to become reduced 
to two molecules of water (4 H
+
 are added to maintain the charge neutrality) (Rich & 
Marechal 2010). While cytochrome c participates primarily in oxidative phosphorylation 
as an electron carrier, it also has a pro-apoptotic role when released into the cytosol by 
facilitating the formation of an apoptosome (Tait & Green 2010). 
Complex V is the final unit in the oxidative phosphylorative pathway. More 
commonly known as the ATP FO/F1 synthetase, complex V does not move electrons, but 
instead it utilizes the proton gradient created by Complex I, III, and IV to regenerate ATP 
from ADP. This large structure is composed of two portions: FO-a ring shaped complex 
containing the ATP synthase FO subunit 6 (encoded by ATP6) which forms a proton 
channel, and F1-a central stalk ending in a ball complex. The FO ring is embedded in the 
inner membrane and through its subunit 6/ATP6, encompasses a channel to allow for the 
passage of H
+
 to move from the intermembrane space into the matrix down its gradient. 
The movement of H
+
 causes the FO ring to rotate, which causes rotation of the central 
stalk (part of the F1 portion). The matrix end of the central stalk has a small hook and is 
connected to the ball-shaped complex of the F1 portion. Rotation of the central stalk (due 
to proton movement through the FO ring) causes the hook at the end of the stalk to disturb 
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the ball-shaped complex in the F1 portion, providing energy for the conformational 
changes leading to ATP synthesis (Rich & Marechal 2010). 
 
Source of ROS generation in the mitochondria 
The electron transport chain is very tightly coupled and the electrical efficiency of 
each complex in individual mitochondria must be perfectly balanced to the other 
complexes. Deviations or changes in any of the complexes can short the electrical circuit 
across the inner membrane. Therefore, the genes transcribing critical electrical 
components in these complexes must be inherited together. Assorted inheritance of these 
genes through sexual recombination would off-set the coupling coefficiency of these 
complexes and the ensuing results would be disastrous for the organism. Therefore, the 
mitochondrial genome (mtDNA), which is vertically inherited from mother to child, 
encodes for the core electrical components of Complex I, III, IV, and V, effectively 
avoiding the combination of incompatible circuit elements (Wallace 2005).  
The inheritance pattern of the core mitochondrial complexes demonstrates the 
importance of maintaining the electrochemical gradient in the mitochondria. Alterations 
in the gradient not only affect ATP generation, but also alter the efficiency of the electron 
movement in the electron transport chain. The movement of electrons through the 
electron transport chain is tightly regulated and controlled, but as they are high energy, 
unstable atomic particles, electrons may occasionally react directly with oxygen instead 
of passing on the respiratory chain. The addition of an electron directly to O2 results in 
the formation of superoxide anion (O2
∙-
), a type of reactive oxygen species, which can be 
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converted to other reactive oxygen species by various chemical reactions. Even under 
optimal conditions, there is always a small electron leak from the electron transport chain 
which results in ROS formation (Adam-Vizi & Chinopoulos 2006). Under non-
physiologic (excessively low or high) metabolic states, the electron leak may become 
greater, leading to greater ROS production (Selivanov et al. 2011). 
The main sites of electron leak are at complex I and complex III. When succinate 
is in abundance, it leads to a high pool of reduced CoQ, which can drive the reverse 
electron transport in Complex I (Lambert & Brand 2009). The mobile electrons in the 
accumulated reduced CoQ proteins in the iron sulfur centers and FMN in Complex I can 
react with O2, leading to superoxide generation. Superoxide production from complex I 
has been implicated in the pathogenesis of Parkinson’s disease, fatal infantile lactic 
acidosis, and Leigh disease (Hirst et al. 2008). ROS produced from Complex I appears to 
be delivered exclusively into the mitochondrial matrix (Lambert & Brand 2009). Another 
site of ROS production on the electron transport chain is Complex III. Like Complex I, 
Complex III can also produce ROS during reverse electron transport, although the rate of 
ROS production in those conditions is thought to be relatively low in comparison 
(Lambert & Brand 2009). Inhibition of the Q-cycle (which recycles oxidized CoQ within 
Complex III) between cyt bH and Qi site by antimycin causes the formation of the 
unstable semiquinone at the Q0 site, which readily transfers its single electron to O2 (Cape 
et al. 2007). ROS produced from Complex III is delivered into both the mitochondrial 
matrix and the intermembrane space (Lambert & Brand 2009). 
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The addition of electrons directly to oxygen produces superoxide, a highly 
reactive non-diffusible reactive oxygen species. Although superoxide is charged and 
incapable of diffusing across membranes, it is converted to hydrogen peroxide by either 
manganese superoxide dismutase (in the mitochondrial matrix) or copper zinc superoxide 
dismutase (in the intermembrane space). The resulting hydrogen peroxide is more stable 
and freely diffusible, and is able to leave the mitochondria to enter the cytoplasm, and 
further into extracellular space, affecting redox metabolism to beyond the mitochondria 
(Giorgio et al. 2007).    
 
Factors affecting ROS production in the mitochondria: effect of membrane potential 
While particular uncoupling drugs can selectively affect ROS production 
specifically in either Complex I or III, the entire electron transport chain is sensitive to 
changes in the mitochondrial electrochemical gradient. The electrochemical gradient is 
the combined effect of the pH gradient and the mitochondrial membrane potential (Δψ). 
Changes in either mitochondrial matrix pH (Lambert & Brand 2004) or Δψ (Selivanov et 
al. 2011; Nicholls 2004) have been shown to affect the mitochondrial ROS production. 
When the mitochondrial membrane potential increases (denoted by a more 
hyperpolarized, or negative Δψ), the mitochondrial matrix is more reduced, making it 
energetically more difficult for the negatively charged electrons to move to the matrix-
side of the complexes. This result in stalling of the electron transport chain, and the 
reduction of alternative acceptors, such as O2, become more favorable. Therefore, the 
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mitochondrial membrane potential is tightly controlled to optimize ATP generation and 
minimize ROS generation.   
 
MPTP: regulation of mitochondrial membrane potential 
 The MPTP was historically discovered in relation to its participation in cell death 
(Crompton 1999). However, the MPTP has also been observed to be active in non-
apoptotic conditions. In the absence of continued calcium stimulation, the MPTP can 
stochastically flicker open and close (Wang et al. 2008). The function of these stochastic 
openings has not been clearly demonstrated, but is thought to regulate mitochondria-
cytosolic crosstalk or mitochondrial metabolism (Wang et al. 2012). One of the 
immediate effects of MPTP flickering is that the transient opening between the 
mitochondrial matrix and cytosol allows for a brief movement of charged solutes 
(<300Da) between these two compartments, causing a dip in the mitochondrial 
membrane potential (Wang et al. 2012; Brenner & Moulin 2012). As fluctuations in the 
mitochondrial membrane potential can modulate ATP generation and ROS production, 
the transient opening of the MPTP is thought be a regulatory means for maintaining the 
mitochondrial membrane potential at approximately -180mV (Huser & Blatter 1999; 
Wang et al. 2012). These transient flickering of the MPTP has also been proposed to 
regulate mitochondrial matrix pH (Ichas & Mazat 1998). 
Like the irreversible mode of opening, this transient form of MPTP opening is 
also sensitive to inhibition by CsA. Similarly, CsA treatment does not completely render 
the MPTP refractory from opening, but instead it raises the stimulus threshold required 
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for it to open. Considering the transient MPTP flickering may be responsible for 
maintaining the mitochondrial membrane potential by acting as a release valve, 
decreasing pore opening through treatment with CsA would theoretically lead to 
increased mitochondrial membrane potential, which has been independently established 
to increase ROS production in the electron transport chain (Korshunov et al. 1997; Hirst 
et al. 2008; Miwa & Brand 2003).  
Our data is consistent with this hypothesis and shows CsA treatment potently 
increases mitochondrial membrane potential, demonstrating that it is a feasible means 
through which CsA could increase mitochondrial ROS. One caveat of our experiments is 
that it only provides an associative link between the increased mitochondrial membrane 
potential and mitochondrial ROS production in the setting of CsA treatment, and future 
studies are need to show a causal effect. One potential means of addressing the issue of 
mitochondrial ROS is the genetic overexpression of mitochondrial antioxidants such as 
manganese dismutase or copper zinc dismutase, which would neutralize any elevated 
mitochondrial ROS and should abolish CsA-induced effects. Additionally, cells isolated 
from cyclophilin D null mice should behave similarly to CsA treated wild-type cells with 
a basal increase in mitochondrial membrane potential and increased mitochondrial ROS 
production.  
 
Global effector molecule: CsA side effects and ROS signaling 
While we show that CsA-induced ROS in endothelial cells promotes cell 
proliferation, other groups have found it to confer toxicity (Redondo-Horcajo et al. 2010). 
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The diverse effects associated with CsA-induced ROS may be due to the promiscuous 
nature of ROS signaling, especially in different cell types. Moreover, the level of ROS 
may be dependent on CsA concentrations.   
Dose-dependent induction of ROS by CsA would have broad clinical significance, 
as variable tissue accumulation of CsA in combination with cell-specific responses to 
CsA-induced ROS may further explain the numerous multi-organ side effects seen with 
CsA treatment. Indeed, CsA-induced ROS can contribute to CsA-associated 
nephrotoxicity. In vivo studies have found CsA treatment increases the glomerular 
synthesis of ROS, thromboxane, and lipid peroxidation products in the kidney (Parra Cid 
et al. 2003). Furthermore, increased ROS has been linked to hypertension pathogenesis, 
as superoxide can react with nitric oxide to generate peroxynitrate, decreasing the pool of 
the vasodilator nitric oxide (Yung et al. 2006). Additionally ROS has been identified as a 
mediator between CsA and the activation of the renal-angiotensin system in the setting of 
transplant associated hypertension (Nishiyama et al. 2003). Taken together, CsA-induced 
ROS may be a viable target for the development of therapies to mitigate adverse effects 
of CsA use.   
 
CsA effects in endothelial cells: aggregation of calcineurin and ROS signaling.  
 As is evident from the literature and our studies, CsA treatment has multiple 
effects. This stems partly from the cell-specific role of calcineurin and the dose-
dependent effects of ROS. Depending on the scale of inhibition or activation of these 
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pathways, the final effect of CsA on cell biology is variable. In endothelial cells 
specifically, CsA negatively regulates the VEGF-calcineurin axis, where maximal 
 
Fig. 4.2. Model of signaling pathways affected by CsA in relation to endothelial 
cell proliferation. As CsA levels increase moderately, it exerts both a pro-
proliferative effect through moderately elevated ROS and a slight anti-angiogenic 
effect through calcineurin inhibition, with an overall pro-growth effect. At high levels, 
CsA induce toxic levels of ROS and maximally inhibit calcineurin, resulting in 
decreased endothelial cell numbers.  
 
calcineurin inhibition blocks angiogenesis (Hernández et al. 2001). Furthermore, CsA-
induced ROS has a gradient effect on proliferation and apoptosis. It is important to 
recognize that CsA treatment in endothelial cells has a dose-dependent effect on both the 
calcineurin and ROS signaling pathways, which results in a bell-shaped effect on 
proliferation and cell numbers (Fig. 4.2.). This model allows for the pro-proliferative 
outcome seen in our studies, but also explains the cytotoxic effects seen at other CsA 
doses. 
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 Clinical Implications 
 
Antioxidant therapy  
We are the first to demonstrate that antioxidant therapy decreases CsA-induced 
tumor growth in an in vivo model. This result raises obvious clinical implication of using 
antioxidants therapeutically for patients on CsA containing drug regiments. Antioxidants 
are a class of drugs with a large therapeutic window, mild side effects, few major drug 
interactions, and can be obtained over-the-counter as health supplements. While large 
clinical trials have failed to show the efficacy of antioxidants for preventing 
cardiovascular disease (Vivekananthan et al. 2003), it nonetheless has been shown to be a 
safe and well tolerated drug. More studies are necessary to determine the exact 
antioxidant, optimal dose, and its effect on outcome. 
One potential point of concern for antioxidant treatment in the setting of cancer is 
highlighted by a recent study which showed increased mortality and decreased survival in 
a mouse model of cancer with antioxidant treatment. In this study, N-acetyl cysteine 
(NAC) and vitamin E treatment increased progression of B-raf and K-ras induced lung 
tumors and reduced the survival of these tumor-bearing mice compared to vehicle treated 
(Sayin et al. 2014). This was thought to be due to disruption of the ROS-p53 axis by 
antioxidants, which would otherwise limit tumor growth. It is important to take into 
consideration that the role of reactive oxygen species, and therefore, antioxidant 
treatment is complex and may have adverse unintended effects.  
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NAC used in our studies is a FDA approved antioxidant, used clinically as an 
antidote for acetaminophen overdose (Atkuri et al. 2007). Other antioxidants such as 
Vitamin C and E may be more applicable for long term use. Given the potential pro-
tumor risk associated with NAC and vitamin E (Sayin et al. 2014), mitochondrially 
targeted antioxidants may be more specific for targeting mitochondrially generated ROS. 
A diet high in antioxidant-rich foods such as fruit and vegetable are recommended for a 
healthy lifestyle, and may be even more important for transplant patients.  
Surgical excision is the mainstay for cutaneous squamous cell carcinoma, but 
chemoradiation is often utilized in setting of transplant-associated skin cancers. Many 
current chemotherapeutic drugs have high toxicity, and some are also carcinogenic or 
mutagenic. Therefore, in transplant patients, it is important to weigh the potential dangers 
of antioxidant treatment with the risks of cancer, and also compare its benefits and 
toxicities with that of the current standard treatments. 
 
Prophylactic use: 
Transplant associated cancers typically occurs years to decades after the onset of 
immunosuppressive treatment. This variable latent period opens up the possibility of 
taking preventive measures to decrease the oncogenic risk. Drugs used for prophylaxis 
must balance the risks and benefits of use, especially for long term use for an adverse 
event which materializes in only 50% of patients (Euvrard et al. 2003). Systemic retinoid 
have shown efficacy as chemopreventative treatments for decreasing the incidence of 
squamous cell carcinoma in transplant patients (Lien et al. 2012; Bettoli et al. 2013), but 
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incurs multiple side effects including a high risk of teratogenicity. While antioxidant 
usage generally results in less severe side effects than systemic retinoid, more studies are 
needed to determine its safety, especially in the light of potential tumor-promoting 
properties discussed earlier. In our experiments, we show that antioxidant treatment in a 
mouse model of melanoma decreases tumor growth, but the ideal goal of prophylactic 
treatment is to decrease both the incidence of disease in addition to disease burden. 
Future studies using spontaneous animal models of skin cancer such as the DMBA-TPA 
chemical carcinogenesis model or UV induced SCC model would be useful to further 
characterize the effect antioxidant prophylaxis on CsA-associated tumors.  
 
Therapeutic use: 
 In addition to preventative use, antioxidants may also be useful as therapeutic 
treatment, in combination with standard therapy for transplant associated cancers. 
Transplant associated skin cancers are much more aggressive and metastatic than their 
spontaneous counterparts (Euvrard et al. 2003). In the case of spontaneous squamous and 
basal cell carcinomas, the tumors remain relatively indolent for long periods of time, and 
carries excellent prognosis if surgically removed. In the case of CsA-associated skin 
cancers, however, invasion occurs much faster, and multi-organ metastasis is not 
uncommon. Moreover, prognosis for CsA-associated skin cancers is much poorer than 
spontaneous skin cancers and current treatments recommended for skin cancers, surgical 
and occasional chemoradiation therapies (Jennings & Schmults 2010) are not always 
sufficient. Therefore, there exists a niche for better treatment options. Here we show 
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CsA-associated tumor growth can be slowed with antioxidant treatment, suggesting 
antioxidants may be utilized as adjuvant therapy, in addition to current standard-of-care, 
to treat transplant associated cancers.  
 
Anti-angiogenic therapy to target CsA-associated cancers  
In our study, we have discerned that CsA treatment increases tumor angiogenesis 
through increased ROS, and antioxidants may be both a prophylactic and therapeutic 
treatment option. Alternatively, there are many existing anti-angiogenic therapies that 
may have a beneficial application for transplant associated cancers. Although 
invasiveness in skin cancers is associated with greater vascularization (Staibano et al. 
1996), anti-angiogenic therapies are not routinely used to treat skin cancers. Anti-
angiogenic therapies for other cancer types have shown mixed results (Bergers & 
Hanahan 2008), reflecting the complexity of the tumor vessel contribution to both disease 
progression and treatment efficacy. Nonetheless, anti-angiogenic drugs are FDA 
approved and well characterized, and may offer treatment benefit for transplant 
associated skin cancers. 
 
Anti-angiogenic target: calcineurin pathway 
One of the questions leading to this study was the paradox of how CsA, a 
calcineurin inhibitor, increased tumor growth. According to the previously defined role of 
calcineurin in endothelial cells, inhibition of calcineurin interferes with VEGF signaling 
in endothelial cells, resulting in decreased tumor angiogenesis and tumor growth in vivo 
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(Baek et al. 2009). The development of calcineurin inhibitors as anti-angiogenic drugs 
was hampered by the clinical experience with CsA usage, which clearly demonstrates 
pro-tumor activities. As we have dissected out the angiogenic component of CsA’s pro-
tumorigenic effect to be calcineurin-independent, it allows calcineurin inhibition to be 
once again considered as an anti-angiogenic target. There are a number of calcineurin 
inhibitors, both small molecule drugs and endogenous inhibitors, which can be employed. 
CsA is a poor choice as it promotes angiogenesis through an independent mechanism. 
From our studies, it would appear FK506 is also an inferior choice as it did not decrease 
tumor growth compared to control treatment. Pimecrolimus, a macrolide antibiotic 
similar to FK506 remains a possibility, but needs to be investigated. While not clinically 
used, other molecules such as DSCR1, autoinhibitory domain (AID) (Perrino 1999), 
cabin-1/cain (Sun et al. 1998), AKAP79 (Kashishian et al. 1998), and the A238L protein 
from the African swine virus (Miskin 1998) are known to inhibit calcineurin directly. 
Additionally, other molecules such as Dyrk-1A (Arron et al. 2006; Gwack et al. 2006) 
can target NFAT phosphorylation, the main effector of calcineurin activation, to block 
calcineurin activity further downstream. VIVIT, a small molecule developed based on the 
NFAT docking sequence, inhibits the calcineurin/NFAT interaction (Yu et al. 2007), and 
is an attractive candidate to selectively inhibit calcineurin activity in endothelial cells. 
Significant work, however, is needed for the development of any of these small molecule 
inhibitors to clinical use in order to address the issues of permeability, stability, and 
pharmacokinetics. Nonetheless, they remain promising novel therapeutic agents for 
selective inhibition of calcineurin-induced tumor angiogenesis.  
121 
 
CHAPTER 5: MATERIALS AND METHODS 
 
Primary endothelial cell isolation 
Primary lung endothelial cells were isolated from 3-4 week old adult mice. 
Briefly, whole lungs were minced and digested in Hanks Balanced Salt Solution (HBSS; 
Invitrogen) containing 10mg/mL type II collagenase (Worthington) and 20µg/mL DNase 
I (Sigma-Aldrich) for 30-45 minutes at 37°C with shaking. The collagenase was 
quenched with equivolume FBS, then filtered through progressively smaller cell strainers 
(100 and 40 μm) and centrifuged. Red blood cells were lysed with ACK Lysing Buffer 
(Invitrogen), then centrifuged and washed once in HBSS with 0.5% BSA (Invitrogen). 
Cells were incubated first with mouse Fc blocking reagent (Miltenyi Biotech) for 5 
minutes on ice, then anti-CD31 biotinylated antibodies (1:100; ebiosciences, Clone 390) 
for 30 minutes at 4°C, rotating, washed once in MACs buffer, and then resuspended in 
MACs buffer with anti-biotin microbeads (Miltenyi Biotech) for 15 minutes before being 
applied to a magnetic column (Miltenyi Biotech). CD31 positive cells were seeded on 0.1% 
gelatin coated plates and cultured in endothelial cell media, Advanced DMEM 
(Invitrogen) supplemented with 15% FBS, 2mM glutamine, 100units/mL penicillin, and 
100µg/mL streptomycin, 25mM Hepes (Invitrogen), 100µg/mL heparin (Sigma-Aldrich), 
and 100µg/mL ECGS (Biomedical Technologies, Stoughton MA). After 7 days, a second 
CD31 selection was performed. Endothelial cell purity was determined by 
immunostaining with anti-CD31 rat antibody (BD Pharmingen). 
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Reagents 
NIM811 was a gift from Novartis. CsA and FK506 (Sigma-Aldrich) for in vitro 
experiments were reconstituted in ethanol at 8.3mM for a stock solution and further 
diluted in sterile water for working solutions and used at 0.25µM and 0.1µM respectively, 
unless indicated otherwise. N-acetyl cysteine (Sigma-Aldrich) was reconstituted in sterile 
water and used at 5mM for in vitro experiments or 40mM for in vivo treatment. 
Mn(III)tetrakis(4-benzoic acid)porphyrin Chloride (Millipore) was diluted in sterile water 
and used at 10µM. Angiotensin II (Sigma-Aldrich) was reconstituted in sterile water and 
used at 100nM. 
 
Animals and Tumor Studies 
WT C57Bl/6 mice were from The Jackson Laboratory. Dscr1 transgenic mice 
with a third copy of Dscr1 targeted into the hypoxanthine phosphor-ribosyltransferase 
locus were generated as previously described (Baek et al., 2009). Calcineurin B
f/f
 mice 
with loxP sites flanking the Calcineurin B gene were originally from The Jackson 
Laboratory. For CsA or FK506 drug treatments, mice were orally gavaged daily with 
10mg/kg of CsA oral solution USP modified (Hospital of University of Pennsylvania 
(HUP) Pharmacy) diluted in peanut oil or 0.15mg/kg of FK506 (HUP Pharmacy) diluted 
in simple syrup, for the duration of the experiment. Mice were 8-12 weeks old. All 
animal experiments were performed according to protocols approved by the University of 
Pennsylvania institutional animal care and use committee. 
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Chemical carcinogenesis skin tumor model 
Mice were treated with a single cutaneous application of 25µg of 7,12-
dimethylbenz(a)anthracene (DMBA; Sigma-Aldrich) in 200µL of acetone on the shaved 
dorsal surface, followed by twice weekly cutaneous applications of 12.5µg 12-O-
tetradecanoylphorbol-13-acetate (TPA; Sigma-Aldrich) in 200µL of acetone for 40 weeks. 
Tumor incidence was palpated by hand weekly. 
 
Melanoma tumor model 
 B16-F10 melanoma cells (ATCC) were cultured in DMEM (Invitrogen) 
containing 10% FBS, 2mM glutamine, 100units/mL penicillin, and 100µg/mL 
streptomycin. For injection, cells were trypsinized, washed in PBS, counted and 
resuspended in sterile PBS. Each mouse received 3x10
5
 cells subcutaneously on the 
dorsal side. Tumor growth was measured by calipers daily. Mice were euthanized if they 
became moribund or tumors became ulcerated prior to experimental endpoint.  
 
Immunofluorescence and CD31 quantification 
 Tumors were harvest from mice after euthanasia and frozen in OCT freezing 
medium (Tissue-Tek), then sectioned for staining. Slides were fixed and permeabilized in 
ice cold acetone for ten minutes, blocked with 5% normal goat serum and 1% BSA. Then 
the slides were incubated overnight at 4° C with rat anti-mouse CD31 antibody (1:50, BD 
Biosciences). Secondary antibody was Alexa 594 goat anti-rat (1:2000, Invitrogen) and 
nuclei were identified with Hoechst33342 (1:1000, Invitrogen). Five random 10X 
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magnification pictures were taken of each slide. Images were taken at RT with a 10× or 
20× magnification objective lens and with a digital camera AxioCAM HRc (Zeiss, 
Thornwood, CT) mounted on Zeiss Imager M1 Axio using Zeiss AxioVision Acquisition 
software (version 4.5). The area of CD31
+
 structures, visible lumens, total vessels, and 
vessels >100µm were counted. Vessel structures for all tumors within a treatment group 
were averaged to determine average and standard deviation.  
 
Miles Assay of vessel permeability 
 200µL of 0.5% sterile solution of Evans blue in PBS was injected tail vein into 
tumor-bearing mice and allowed to distribute into tissues for 30 minutes, followed by 
animal sacrificing and tumor removal. Excised tumors were weighed and 500µL 
formamide was added to each sample and incubated at 55ºC for 24-48 hours to extract the 
Evans blue. The tumor/formamide mixture was pelleted and the dye concentration in the 
supernatant was measured with absorbance at 610nm and calculated as ng Evans blue 
extravasated per mg tissue.  
 
Proliferation and cell growth 
Endothelial cells were plated in triplicates at 5 x 10
3
 cells per well in 0.1% gelatin 
coated 24-well tissue culture plates. Cells were counted daily or every other day. Media 
was changed every 3 days.  
 
BrdU incorporation  
125 
 
2.5 x 10
3
 endothelial cells were plated onto 0.1% gelatin coated glass coverslips. 
10µM BrdU (BD Biosciences) was added to cells for 1.5 hours at 37°C. Cells were fixed 
with 4% paraformaldehyde (PFA) for 15 minutes, permeabilized with 0.1% TBST for 15 
minutes, and DNA was denatured with 2N HCL for 30 min. Endothelial cells were 
stained with anti-BrdU mouse antibody (1:50, Dako) for 1 hour at room temperature. 
Secondary antibody was Alexa 594 goat anti-rat (1:2000, Invitrogen) and nuclei were 
identified with Hoechst33342 (1:1000, Invitrogen). Seven random 10X magnification 
pictures were taken of each slide and BrdU positive cells and total cell number were 
counted. 
 
Tunel apoptosis assay  
To measure apoptosis, in situ terminal deoxynucleotidyltransferase-mediated 
dUTP nick end labeling (TUNEL) labeling was performed using the DeadEnd 
Fluorometric TUNEL System (Promega, Madison, WI) according to manufacturer's 
instructions. Briefly, endothelial cells were washed with PBS and trypsinized, then fixed 
with 4% PFA for 20 minutes on ice. Cells were permeabilized by 70% EtOH for 4 hours 
at -20C, washed with PBS, then incubated in equilibration buffer for 5 minutes. Cells 
were then incubated with TdT reaction mix for 60 minutes, washed, and resuspended in 
20mM EDTA to stop the reaction. Cells were then incubated with 5µg/mL propidium 
iodide (Sigma-Aldrich) with 1mg/mL RNase for 20 minutes at room temperature. Flow 
cytometry was performed on a FACS Canto flow cytometer (BD Biosciences) and 
analyzed with FlowJo Software (TreeStar, Ashland, OR).  
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Migration assay 
Basal endothelial cell media, Advanced DMEM (Invitrogen) supplemented with 
0.5% FBS, 2mM glutamine, 100units/mL penicillin, and 100µg/mL streptomycin, 25mM 
Hepes (Invitrogen), and 100µg/mL heparin (Sigma-Aldrich) was placed in the lower 
chamber of a modified Boyden chamber (Corning) separated by a filter with 8µm pores. 
Endothelial cells were serum starved overnight with basal endothelial cell media, treated 
with experimental reagents for 2 hours, then trypsinized and resuspended in basal media 
at 2 x 10
5
 cells/mL. 2 x 10
4
 cells were plated in the upper chamber and allowed to 
migrate for 3 hours at 37ºC. The filters were stained with Diff-Quick solution (Baxter, 
Miami, FL) and images were taken at RT with a 10× or 20× magnification objective lens 
and with a digital camera AxioCAM HRc (Zeiss, Thornwood, CT) mounted on Zeiss 
Imager M1 Axio using Zeiss AxioVision Acquisition software (version 4.5). 5 random 
images were taken of the filters and the number of cells that migrated across the filter was 
counted. 
 
Matrigel tube formation assay 
 3 x 10
5
 primary lung endothelial cells in 600µL optiMEM with 1% FBS were 
plated on top of 600µL of polymerized matrigel in a 12 well plate. Cells were incubated 
at 37ºC and 5% CO2 to allow for tube formation. Images were taken at indicated time 
points.  
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AdCre infection 
For in vitro experiments, primary lung endothelial cells from CnB
f/f
 mice were 
infected with Cre recombinase adenovirus (Ad5CMVCre; University of Iowa, Gene 
Transfer Vector Core) at 500 MOI overnight, followed by PBS wash and media change. 
After two passages, cells were assessed for Calcineurin B deletion by immunoblotting for 
calcineurin A protein, which degrades in absence of calcineurin B.  
 
DCFDA staining 
 DCFDA (Abcam) staining was performed following manufacturer’s instructions. 
Briefly, cells were treated with drug for 24 hours, then washed and stained with 25µM 
DCFDA for 45 minutes at 37ºC. Signal was read at 535nm. 
 
Mitosox and TMRE Staining  
Mitosox (Invitrogen) and TMRE (Invitrogen) staining of endothelial cells in vitro 
were done following manufacturer’s instructions. Briefly, endothelial cells were washed 
with PBS and trypsinized, and then resuspended in calcium and magnesium containing, 
phenol red free HBSS (Gibco) supplemented with 0.1µM sodium pyruvate (Sigma) and 
5µM Mitosox or 100nM TMRE. Cells were incubated for 10 min (Mitosox) or 20 min 
(TMRE) at 37°C in the dark, then flow cytometry was performed using a FACS Canto 
flow cytometry machine reading at 610 or 613nm (Mitosox) or 575 nm (TMRE). The 
results were analyzed with FlowJo software (TreeStar, Ashland, OR).  
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Western blotting  
Endothelial cells were scraped from tissue culture dishes and lysed with RIPA 
buffer supplemented with a protease inhibitor cocktail (Roche). Whole cell lysates were 
separated by SDS-PAGE, transferred to nitrocellulose membrane, and probed with the 
following antibodies: p-ERK, total ERK, p-AKT, total AKT (Cell Signaling 
Technologies), Calcineurin A (Santa Cruz), β-actin (Sigma). To measure relative gel 
densities, band densities were quantified with densitometry analysis using ImageJ 
software (NIH) and then normalized to β-actin, or if blotting for a phospho-protein, the 
total-protein.  
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